

Table 1. List of Representative Liposome-Encapsulated Hbs (LEH) Extensively Studied Aiming at Industrialization and Other Potential Encapsulated Hbs Using Biodegradable Polymers

| product name | group | characteristics | current status |
|-----------------------------------|---|---|----------------|
| Hb vesicles (HbV) | Waseda Univ. and Keio Univ. | 1. Pasteurization of HbCO at 60 °C for virus inactivation 2. Lipid composition to improve blood compatibility 3. PEG modification and deoxygenation for 2 yr storage 4. [Hb] = 10 g/dL | preclinical |
| Neo Red Cells (NRC) | Terumo Corp. | 1. Inositol hexaphosphate to regulate P_{50} (= 40–50 Torr) 2. Lipids: HSPC/cholesterol/fatty acid/PEG-lipid 3. Storage in a refrigerator for 6 months 4. [Hb] = 6 g/dL | preclinical |
| artificial red cells (ARC) | NOF Corp. and Waseda Univ. | 1. Polymerized lipids (DODPC) for stabilization 2. Storage in powdered or frozen state 3. Difficulty in degradation in RES | suspended |
| liposome-encapsulated Hb (LEH) | US Naval Research Laboratory | 1. Freeze-dried powder with trehalose 2. Low Hb encapsulation efficiency 3. Thrombocytopenia, complement activation | suspended |
| synthetic erythrocytes | Rush-Presbyterian-St. Luke's Medical Center, Univ. Illinois | 1. The first attempt of LEH | suspended |
| Hb-loaded particles (HbP) | East China Univ. of Science and Technology | 1. Hb encapsulation by poly(ϵ -caprolactone) (PCL) and poly(ϵ -caprolactone-ethylene glycol) (PCL-PEG) 2. Double emulsion and solvent diffusion/evaporation method 3. Biodegradable | basic study |
| polymersome-encapsulated Hb (PEH) | The Ohio State Univ. | 1. Self-assembly of amphiphilic diblock copolymers composed of poly(ethylene oxide) (PEO), poly(caprolactone) (PCL), and poly(lactide) (PLA) 2. Biodegradable and biocompatible | basic study |

Table 2. Physicochemical Characteristics of Hb Vesicles

| parameter | |
|---|--|
| particle diameter | 250–280 nm |
| P_{50} (O_2) ^a | 25–28 Torr |
| [Hb] | 10 g/dL |
| [heme] | 6.2 mM |
| [metHb] | <3% |
| [HbCO] | <2% |
| suspending medium | physiologic saline solution (0.9% NaCl) |
| colloid osmotic pressure | 0 Torr |
| intracellular Hb concentration | ca. 35 g/dL |
| lipid composition | DPPC/cholesterol/DHSG/ DSPE-PEG ₅₀₀₀ |
| ζ potential ^b | -18.7 mV |
| weight ratio of Hb to lipids | 1.6–1.9 (w/w) |
| viscosity ^c | 3.8 cP |
| lamellarity | nearly 1 |
| stability for storage at room temperature | >2 years, purged with N ₂ |
| circulation half-life | 35 h (rats) |

^a Measured with a Hemox Analyzer (pH 7.4, 37 °C). ^b Measured with a Zeta-Sizer Nano ZS ([NaCl] = 20 mM, pH 7.4). ^c Measured with Anton Parr Rheometer M301 (268 s⁻¹, 25 °C).

Table 3. Characteristics of Hb-Vesicles As a Transfusion Alternative

- Human derived Hb solution is purified rigorously by pasteurization and ultrafiltration. The blood type antigens and pathogens are eliminated for utmost safety.
- Encapsulation of concentrated Hb solution (>35 g/dL), like RBCs.
- Small particle size (250 nm) for homogeneous distribution in the plasma phase of circulating blood.
- Shielding of the side effects of molecular Hbs by the lipid membrane.
- PEG modification for dispersion stability for long-term storage and in the bloodstream.
- Surface properties of HbV (PEG, negative charge, etc.) for blood compatibility.
- Prompt degradation and excretion of the components after entrapment in RES.
- Sufficient oxygen transporting capacity ([Hb] = 10 g/dL, cf, [Hb] of blood = 12–15 g/dL).
- Physicochemical properties are easily adjustable because of the nature of the "molecular assembly".

tion because of the difficulty in excretion. Subsequently, it was clarified that selection of appropriate lipids (phospholipid/cholesterol/negatively charged lipid/PEG-conjugated phospholipid) and that their composition is important to enhance the

stability of nonpolymerized liposomes (45, 68). Surface modification of liposomes with PEG-conjugated lipids is sufficient for dispersion stability (69). In fact, in comparison to RBCs, HbV is highly resistant to hypotonic shock, freeze-thawing, and enzymatic attack by phospholipase A₂ (70).

We investigated the possibility of long-term preservation of HbV during storage for two years through a combination of deoxygenation and PEG modification (71). As little as 0.3 mol % PEG-conjugated lipid stabilizes the dispersion state and prevents aggregation and fusion for two years through steric hindrance (71–73). The original metHb content (ca. 3%) before preservation decreased gradually to less than 1% after 1 month because of the presence of a reductant, such as homocysteine, inside the vesicles that consumed the residual O₂ and gradually reduced the trace amount of metHb. The rate of metHb formation was strongly dependent on the O₂ partial pressure: a lack of increase in the metHb formation was observed because of the intrinsic stability of the deoxygenated Hb. In fact, the metHb content did not increase for two years. These results suggest the possibility that the HbV suspension can be stored at room temperature for at least two years, which would enable stockpiling of HbV for any emergency.

2.3. Vesicular Surface Modification with PEG and Negative Charges for Blood Compatibility. Liposome is not a solute: it is a particle in a suspension. The particle surface might be recognized, leading to interaction with blood components including complements. The so-called *injection reaction*, or pseudoallergy, results from complement activation, giving rise to anaphylatoxins, which trigger various hypersensitivity reactions. This reaction is observed sometimes not only with liposomal products (74), but also with fat emulsions (75), and a perfluorocarbon emulsion (76). Therefore, examination of blood compatibility of encapsulated Hbs is important for clinical use. Transient thrombocytopenia and pulmonary hypertension in relation to complement activation is an extremely important hematologic effect observed in rodent models after infusion of LEH (containing DPPG: 1,2-dipalmitoyl-*sn*-glycero-3-phosphatidylglycerol) developed by the US Naval Research Laboratory (77, 78) and other products. In our group, exchange transfusion of prototype HbV (containing DPPG, no PEG modification) in anesthetized rats engendered transient thrombocytopenia and slight hypertension (79). Similar effects were also observed for administration of negatively charged liposomes




Figure 4. Effect of negatively charged vesicles on encapsulation capability and blood compatibility of HbV. (a) Chemical structures of negatively charged lipids, 1,5-*O*-dihexadecyl-*N*-succinyl-L-glutamate (DHSG) and 1,2-dipalmitoyl-*sn*-glycero-phosphatidylglycerol (DPPG). (b) Effect of DHSG on encapsulation efficiency of Hb (35 g/dL). (c–f) Circulation levels of platelets (c) and white blood cells (d) after intravenous infusion of vesicles containing 9 mol % DHSG (DHSG-vesicles) or 9 mol % DPPG (DPPG-vesicles) in rats (lipids; 280 mg/kg body weight). The right side graphs show the initial fluctuations in platelets (e) and white blood cells (f).

(80, 81). The transient reduction in platelet counts caused by complement-bound liposomes was also associated with sequestration of platelets in the lung and liver. Such nonphysiological platelet activation probably engenders initiation and modulation of inflammatory responses because platelets contain several potent proinflammatory substances. A negatively charged lipid is required for encapsulating a large amount of Hb using a minimum amount of lipids (46–48). Therefore, we had to overcome the problem of conventional negatively charged vesicles to achieve blood compatibility. In the present formation of HbV, we use a negatively charged lipid (DHSG; 1,5-*O*-dihexadecyl-*N*-succinyl-L-glutamate) and confirmed the considerable improvement of Hb encapsulation efficiency (Figure 4a,b). It must be emphasized that the present vesicle formulation for HbV apparently does not induce thrombocytopenia or complement activation in animal experiments (Figure 4c–f) (82, 83), probably because the present HbV contains PEG-modification and a different type of negatively charged lipid (DHSG), not DPPG or a fatty acid.

Ikeda and his co-workers (83–86) thoroughly examined blood compatibility of HbV to human blood *in vitro*. The present PEG-modified HbV containing DHSG did not affect the extrinsic or intrinsic coagulation activities of human plasma, although HbV containing DPPG and no PEG modification tended to shorten the intrinsic coagulation time. The kallikrein-kinin cascade of the plasma was activated slightly by the prototype DPPG-HbV, but not by the present PEG-DHSG-HbV. The exposure of human platelets to high concentrations of the present HbV (up to 40%) *in vitro* did not cause platelet activation and did not adversely affect the formation and secretion of prothrombotic substances or proinflammatory substances that are triggered by platelet agonists. These results imply that HbV, at concentrations of up to 40%, has aberrant interactions with neither unstimulated nor agonist-induced platelets. It can be concluded that the present PEG-DHSG-HbV has higher blood compatibility.


For surface modification of HbV with PEG chains, several PEG-conjugated lipids having amino acid backbone have been synthesized, as presented in Figure 5b,c (87, 88). For other applications, these PEG-conjugated lipids are available to modify the surfaces of not only HbV but also lipid vesicles. Because the PEG-lipids having a large hydrophilic group form thermo-

dynamically unstable self-assemblies, called micelles (73), they easily dissociate to monomers and spontaneously incorporate only to the outer surface of preformed HbV, as illustrated in Figure 5d (45, 72). Using this method, the required amount of PEG-conjugated lipid can be reduced by half or less because only the outer surface of HbV requires PEG chains. In addition, the PEG chains extending from the inner surface are expected to reduce the interior volume for encapsulation because of their exclusion volume effect. Therefore, modification only to the outer surface is important to encapsulate large amounts of Hb in lipid vesicles. To immobilize the hydrophilic macromolecules stably, such as PEG chains and proteins on lipid vesicles, a large hydrophobic anchor having a tetraacyl structure has been synthesized (Figure 5c,e). It has been confirmed that this hydrophobic anchor can stably immobilize PEG chains of high molecular weight (Mw 12 500) or water-soluble proteins (87, 89). These surface modification technologies and lipid chemistry have been applied to the development of other functional biomaterials (87–93).


2.4. Circulation Time, Biodistribution, and Metabolism. The dosage of blood substitutes is expected to be considerably larger than those of other drugs, while their circulation time is considerably shorter than that of RBCs. Therefore, their biodistribution, metabolism, excretion, and side effects must be characterized in detail, especially in relation to the reticuloendothelial system (RES, alternatively, the mononuclear phagocytic system, MPS). Normally, free Hb released from RBCs is bound rapidly to haptoglobin and is consequently removed from circulation by hepatocytes. However, when the Hb concentration is greater than the haptoglobin binding capacity, unbound Hb is filtered through the kidney, where it is actively absorbed. Hemoglobinuria and eventual renal failure occur when the kidney reabsorption capacity is exceeded. The encapsulation of Hb in vesicles completely suppresses renal excretion. However, HbV in the bloodstream is ultimately captured by phagocytes in the RES in much the same manner as senescent RBCs are, as confirmed by radioisotope ^{99m}Tc -labeled HbV injection (42, 94). The circulation half-life is dose-dependent: for the dosage of 14 mL/kg body weight, the circulation half-life was 34.8 h in rats and 62.6 h in rabbits (Figure 6a). The HbV are finally distributed mainly in the liver,

Poly(ethylene glycol)-conjugated lipids

(a) Phospholipid type



(b) Glutamic acid type



(c) Lysine type





Figure 5. Surface modification of HbV with PEG chains. (a–c) Chemical structures of PEG-conjugated lipids. (a) PEG(5000)-DSPE is commercially available and widely used for surface modification of lipid vesicles. (b) Glutamic acid-type and (c) lysine-type PEG-conjugated lipids were reported previously (87, 88). (d) PEG-modification of the HbV using the spontaneous incorporation of a PEG-lipid into the bilayer membrane (72). (e) Immobilization of the large water-soluble polymers on the bilayer membranes (87, 89).




Figure 6. Circulation kinetics and organ distribution of HbV labeled with technetium-99m after top-loading intravenous infusion (14 mL/kg) in rats and rabbits (94). (a) Elimination profiles of HbV from blood. (b) Static gamma camera images of a rabbit acquired at 2, 24, and 48 h after HbV infusion.

spleen, and bone marrow (Figure 6b). The species-dependent circulation time is inferred to be dependent upon the species-specific weight balance of phagocyte organs, particularly the liver, spleen, and bone marrow, against body weight (94). The

circulation half-life in the case of the human body can be estimated as about 2–3 days at the same dosage.

It is generally accepted that the liposome clearance by RES at a small dosage is accelerated by opsonization (absorption of plasma proteins such as antibodies and complements on the liposomal surface). In fact, PEG-modification prevents opsonization for prolonged circulation times (95). However, considering a condition in which the dosage of HbV is extremely high and requires a considerable amount of opsonins, and in which HbV does not induce complementary activation (82, 83), then opsonin-dependent phagocytosis would not be a major component in the case of HbV with a large dosage. Actually, opsonin-independent phagocytosis, a direct recognition by macrophages, has been clarified in some studies (96, 97).

Analysis of the spleen by transmission electron microscopy (TEM) 1 day after infusion of HbV revealed the presence of HbV particles in the phagosomes of macrophages (98) (Figure 7). However, after 7 days, the HbV structure cannot be observed. We confirmed transient splenomegaly with no irreversible damage to the organs and complete metabolism within a week. The phagocytic activity transiently, but not completely, decreased 1 day after injection, and it turned to increasing at 3 days. The influence on the defense function and its mechanism has been carefully examined in the ongoing research. Immunohistochemical staining with a polyclonal anti-human Hb antibody was used as the marker of Hb in the HbV. Results clarified that HbV had almost disappeared in both the spleen and liver after 7 days.

Bilirubin and iron are believed to be released during metabolism of Hb, but our animal experiments of topload infusion, daily repeated infusions, and 40% blood exchange showed that neither of those products increased in the plasma within 14 days (99–101). Bilirubin would normally be excreted in the bile as a normal pathway; no obstruction or stasis of the bile is expected to occur in the biliary tree. Berlin blue staining




Figure 7. Histopathological examination of livers and spleens of rodents after injection of HbV. (a) Hamster liver 1 h after injection of fluorescence-labeled HbV, observed by a confocal laser scanning microscopy. The strong fluorescence indicates that HbV particles accumulate in Kupffer cells. (b) TEM of rat spleen macrophage 1 day after injection of HbV. The small black dots are HbV particles in phagosomes. The particles disappeared within a week (data not shown) (98). (c) Rat liver 1 day after injection of HbV. It was immunohistochemically stained with anti-human Hb antibody. The red parts indicate the presence of human Hb in HbV. It disappeared within a week (data not shown) (98). (d) Rat liver 7 days after injection of HbV. It was immunohistochemically stained with anti-methoxy-PEG antibody. The brown parts indicate the presence of PEG derived from PEG-lipid of HbV during the degradation. Fourteen days after injection, PEG was not detectable (data not shown) (102). (e) Rat spleen 3 days after 40% exchange transfusion with HbV. It was stained with Giemsa method. A large amount of blue cells, erythroblasts, are seen, indicating the enhanced hematopoiesis for the complete recovery of hematocrit within one week, while HbV are degraded in RES (101).

revealed considerable deposition of hemosiderin in the liver and spleen, even after 14 days. Moderate splenomegaly and hemosiderin deposition were also confirmed in the spleen after injection of stored RBCs, partly because of the accumulation and degradation of stored RBCs with lowered membrane deformability and shortened circulation half-life (101).

As for membrane components of Hb-vesicles, the plasma cholesterol level elevated transiently 3 days after injection; cholesterol was released from macrophages after degradation of HbV in phagosomes (99, 101). It was recently clarified using ^3H -cholesterol that cholesterol of HbV is released from macrophages to blood; it is ultimately excreted in feces. The PEG chain is widely used for surface modification of liposomal products. The chemical cross-linker succinic acid ester of PEG-conjugated phospholipid is susceptible to hydrolysis to release PEG chains during metabolism. Actually, immunohistochemistry using an anti-methoxy-PEG antibody clarified that PEG had disappeared from the liver and spleen in one week (102). The released PEG chains, which are known as inert macromolecules, are expected to be excreted in urine through the kidneys (103).

To determine the physiological capacity of RES for degradation of HbV, we tested massive intravenous doses by daily repeated infusion of 10 mL/kg body weight/day into Wistar rats for 14 days. The cumulative dosage was 140 mL/kg body weight (Hb and lipids, 20 689 mg/kg body weight). The total volume was equal to 2.5 times the total blood volume (56 mL/kg body weight) (100). Although splenohepatomegaly was considerable,




Figure 8. Artificial methHb reduction systems in HbV. (a) Coencapsulation of thiols (RSH), such as glutathione and homocysteine, reduces methHb. However, thiols react with O_2 to generate O_2^- and H_2O_2 . A more reactive thiol such as cysteine shows extremely rapid reaction with O_2 and adversely facilitates methHb formation. Coencapsulation of catalase effectively eliminates H_2O_2 and prevent such reactions (52, 53, 56). (b) Photoreduction system by coencapsulation of flavin mononucleotide (FMN) and an electron donor such as EDTA and methionine. Visible light irradiation (435 nm) primarily converts FMN to the photoexcited triplet FMN^* , and this reacts with two electron donors (D) to generate FMNH_2 . MethHb is rapidly reduced once FMNH_2 is produced (54). (c) During autoxidation of Hb and in blood circulation, H_2O_2 is a potent methHb enhancer. A combination of L-tyrosine (Tyr) and methHb effectively eliminates H_2O_2 and prolongs the functional lifetime of HbV (55).

all rats tolerated the infusions; their body weight increased during the succeeding 14 days until their intended sacrifice. The phagocytosed HbV had disappeared, though the considerable hemosiderin deposition was confirmed in the spleen, liver, kidney, adrenal gland, and bone marrow. We were unable to define a lethal dose of HbV in this experiment.

The profile of liposome clearance is species-dependent. More precise data are necessary to extrapolate the phenomena observed in animal experiments to humans. However, these results imply that the metabolism of HbV and excretion are within the physiological capacity that has been well-characterized for the metabolism of senescent RBCs and conventional liposomal products.

2.5. Regulation of O_2 Transporting Capability (MetHb Reduction, $P_{50}(\text{O}_2)$). Actually, Hb encapsulation provides a unique opportunity to add new functions to particles by coencapsulation or embedding of functional molecules (52–56, 104–106). MethHb formation of HbV during the preservation is completely prevented simply by deoxygenation. However, autoxidation of HbO_2 is initiated once HbV is administered into the bloodstream because the entire methHb enzymatic system is eliminated during the Hb purification for the utmost safety from infection. An artificial methHb reducing system is required to prolong the O_2 -carrying capacity of HbV. We have tested coencapsulation of reductants to directly reduce methHb and a photoreduction system using a photosensitizer such as flavin mononucleotide (FMN). A more practical method is to create an artificial enzymatic system using L-tyrosine (Tyr) and methHb that eliminates H_2O_2 as does catalase (Figure 8).

Without a chemical modification of Hb, O_2 binding affinity (expressed as $P_{50}(\text{O}_2)$, O_2 tension at which Hb is half-saturated




Figure 9. Regulation of physicochemical properties of HbV for versatile applications. (a) Oxygen dissociation curves of HbVs. Oxygen affinity (P_{50} , partial pressure of oxygen at which Hb is half-saturated with oxygen) is regulated by coencapsulation of PLP (105, 106). (b) Colloid osmotic pressure (COP) of chemically modified Hb solutions increase with the Hb concentration (15). In contrast, HbV particles have no oncotic effect. The figure shows 20 Torr when HbV is suspended in 5% rHSA. XLHb, intramolecularly cross-linked Hb. (c) Rheological properties of HbV suspended in various plasma substitute solutions (122). [Hb] = 10 g/dL, 25 °C.

with O_2) of HbV can be regulated by coencapsulation of an allosteric effector (105, 106) (Figure 9a). The $P_{50}(O_2)$ of purified Hb in a saline solution (in the presence of Cl^-) is about 14 Torr; Hb strongly binds O_2 and does not release O_2 at 40 Torr (partial pressure of mixed venous blood). Historically, it has been regarded that the O_2 affinity is expected to be regulated similarly to that of RBC, namely, about 25–30 Torr, using an allosteric effector or by a direct chemical modification of the Hb molecules. This enables sufficient O_2 unloading during blood microcirculation, as evaluated by the arterio-venous difference in the levels of O_2 saturation in accordance with an O_2 equilibrium curve. Pyridoxal 5'-phosphate (PLP) is coencapsulated in HbV as an allosteric effector to regulate $P_{50}(O_2)$ (105, 106). The main binding site of PLP is the N-terminal of the α -chain and β -chain and β -82 Lysine within the β -cleft, which is part of the binding site of the natural allosteric effector, 2,3-diphosphoglyceric acid (2,3-DPG). The bound PLP retards the dissociation of the ionic linkage between the β -chains of Hb during conversion of deoxy to oxyHb in the same manner as 2,3-DPG does. Therefore, the O_2 affinity of Hb decreases in the presence of PLP. The $P_{50}(O_2)$ of HbV can be regulated to 8–150 Torr by coencapsulating the appropriate amount of PLP or inositol hexaphosphate as an allosteric effector. Equimolar PLP to Hb (PLP/Hb = 1/1 by mol) was coencapsulated, and $P_{50}(O_2)$ was regulated to 18 Torr. Furthermore, $P_{50}(O_2)$ was regulated to 32 Torr when the molar ratio PLP/Hb was 3/1. The O_2 affinities of HbV can be regulated easily without changing other physical parameters, whereas in the case of the other modified Hb solutions, their chemical structures determine their O_2 binding affinities. Consequently, regulation is difficult. The present HbV contains PLP at PLP/Hb = 2.5 by mol; the resulting $P_{50}(O_2)$ is about 25–28 Torr, which shows sufficient O_2 transporting capacity as a transfusion alternative. Actually, HbV has been shown to provide O_2 -transport capacity that is both sufficient and comparable to that of RBCs in experiments related to extreme blood exchange (68, 69, 79, 105, 107, 108) and fluid resuscitation from hemorrhagic shock (102, 109–112) (Figure 10). A recent experiment of HbV as a priming solution for cardiopulmonary bypass (CPB) in a rat model showed that HbV protects neurocognitive function by transporting O_2 to brain tissue even when the hematocrit is reduced markedly (113).

The appropriate O_2 binding affinities for O_2 carriers have not yet been decided completely. However, the easy regulation of the O_2 binding affinity might be useful to meet the requirement of clinical indications such as oxygenation of ischemic tissues. The $P_{50}(O_2)$ of HbV without PLP and Cl^- is 8–9 Torr. This formulation is effective for targeted O_2 delivery to anoxic tissues caused by reduced blood flow (107, 114, 115).




Figure 10. (a) Scheme depicting the experimental protocol of hemorrhagic shock and resuscitation (102). Shock was induced by withdrawing 50% of circulating blood volume from Wistar rats. After 15 min, they were resuscitated with either HbV suspended in recombinant human serum albumin (HbV/rHSA) or shed autologous blood (SAB). (b) blood pressure, (c) lactate, (d) pH, and (e) hematocrit (Hct). Mean \pm SD. B, Baseline; AB, after bleeding; BI, before injection (B–6 h, $n = 24$; 1–14 days, $n = 5$).

2.6. Rheological Properties and Their Physiological Implications for Tissue Oxygenation. The extremely high concentration of the HbV suspension ([Hb] = 10 g/dL; [lipids] = 6 g/dL, volume fraction, ca. 40 vol %) imparts an O_2 carrying capacity that is comparable to that of blood. The HbV suspension does not possess a colloid osmotic pressure (COP), because one HbV particle (ca. 250 nm diameter) contains about 30 000 Hb molecules. In fact, HbV acts as a particle, not as a solute. Therefore, HbV must be suspended in or conjoined with an aqueous solution of a plasma substitutes. This requirement is identical to that for emulsified perfluorocarbon, which does not possess COP (116, 117); it contrasts to characteristics of other Hb-based O_2 carriers, intramolecular cross-linked Hbs, polymerized Hbs, and polymer-conjugated Hbs, which all possess very high COP as protein solutions (15, 118) (Figure 9b).

Table 4. Publications of Preclinical Studies Aiming at Applications of Hb-Vesicles for a Transfusion Alternative and for Oxygen Therapeutics

| indication | ref |
|---|--------------------------------|
| 1. Resuscitative fluid for hemorrhagic shock | 102, 109–112 |
| 2. Hemodilution | 68, 69, 79, 101, 105, 107, 108 |
| 3. Priming fluid for extracorporeal membrane oxygenator (ECMO) for cardiopulmonary bypass | 113 |
| 4. Perfusate for resected organs (transplantation) | 24, 129 |
| 5. Oxygenation of ischemic brain (stroke) | 130 |
| 6. Oxygenation of ischemic skin flap (plastic surgery) | 115, 127, 128 |
| 7. Tumor oxygenation for sensitization to irradiation | 131 |
| 8. CO carrier for cytoprotection at reperfusion | 132 |

Animal tests of HbV suspended in plasma-derived HSA or rHSA showed an O₂ transporting capacity that is comparable to that of blood (110, 113). We reported previously that HbV suspended in plasma-derived HSA or rHSA was almost Newtonian: no aggregation was detected microscopically (68, 69). In Japan, rHSA was very recently approved for clinical use, in May 2008 (119), but various plasma substitutes are used worldwide, such as hydroxyethyl starch (HES), dextran (DEX), and modified fluid gelatin (MFG). The selection among these plasma substitutes is best determined not only according to their safety and efficacy, but also according to their associated price, experience of clinicians, and customs of respective countries. Water-soluble polymers generally interact with particles such as polystyrene beads, liposomes, and RBCs to induce aggregation or flocculation (120, 121). For that reason, it is important to determine the compatibility of HbV with these plasma substitutes. With that background, we studied rheological properties of HbV suspended in these plasma substitute solutions using a complex rheometer and a microchannel array (122). The rheological property of an Hb-based O₂ carrier is important because the infusion amount is expected to be considerably large, which might affect the blood viscosity and hemodynamics.

The HbV suspended in rHSA was nearly Newtonian (Figure 9c). Its viscosity was similar to that of blood, and the mixtures with RBCs at various mixing ratios showed viscosities of 3–4 cP. Other polymers, HES, DEX, and MFG, induced flocculation of HbV, possibly by depletion interaction, and rendered the suspensions as non-Newtonian with the *shear-thinning* profile (122). These HbV suspensions showed high viscosity and a high storage modulus (*G'*) because of the presence of flocculated HbV. On the other hand, HbV suspended in rHSA exhibited a very low *G'*. The viscosities of HbV suspended in DEX, MFG, and high-molecular-weight HES solutions responded quickly to rapid step changes of shear rates of 0.1–100 s⁻¹ and a return to 0.1 s⁻¹, indicating that flocculation formation is both rapid and reversible. Microscopically, the flow pattern of the flocculated HbV perfused through microchannels (4.5 μm deep, 7 μm wide, 20 cmH₂O applied pressure) showed no plugging. Furthermore, the time required for passage was directly related to the viscosity.

It has been regarded that lower blood viscosity after hemodilution is effective for tissue perfusion. However, microcirculatory observation shows that, in some cases, lower “plasma viscosity” decreases shear stress on the vascular wall, causing vasoconstriction and reducing the functional capillary density (123). Therefore, an appropriate viscosity might exist, which maintains the normal tissue perfusion level. The large molecular dimension of HbV can result in a transfusion fluid with high viscosity. A large molecular dimension is also effective to reduce vascular permeability and to minimize the reaction with NO and CO as vasorelaxation factors (24, 25, 30, 31)



Figure 11. Crystal structure of HSA with myristate (PDB ID: 1BJ5) from ref (136).

(see Figure 3). These new concepts suggest reconsideration of the design of artificial O₂ carriers (124). Actually, new products are appearing, although they are in the preclinical stage, not only HbV but also zero-link polymerized Hb (125) and others with larger molecular dimensions and higher O₂ affinities (126). Erni et al. clarified that HbV with a high O₂ binding affinity (low *P*₅₀(O₂), such as 8–15 Torr) and high viscosity (such as 11 cP) suspended in a high-molecular-weight HES solution was effective for oxygenation of an ischemic skin flap (115, 127, 128). That study showed that HbV retains O₂ in the upper arterioles, then perfuses through collateral arteries and delivers O₂ to the targeted ischemic tissues, a concept of targeted O₂ delivery by an Hb-based O₂ carrier (114). A high O₂ binding affinity (low *P*₅₀(O₂)) would also be effective to improve the O₂ saturation of Hb in pulmonary capillaries when exposed to a hypoxic atmosphere or with an impaired lung function. Some plasma substitutes cause flocculation of HbV and hyperviscosity. However, reports show that hyperviscosity would not necessarily be deteriorative and might be, in some cases, advantageous in the body (32). HbV provides a unique opportunity to manipulate the suspension rheology, *P*₅₀(O₂), and other physicochemical properties, not only as a transfusion alternative, but also for other clinical applications such as oxygenation of ischemic tissues and ex vivo perfusion systems (129–132) (Table 4).

3. ALBUMIN-HEMES AS O₂ CARRYING PLASMA PROTEINS

3.1. HSA Incorporating Synthetic Fe²⁺ Porphyrin (HSA-FeP). HSA (Mw: 66 500) has a remarkable ability to bind a wide variety of exogenous compounds in the human circulatory system (133). This carrier protein comprises 3 homologue helical domains (I–III) with 9 loops formed by 17 disulfide linkages; each domain contains 2 subdomains (A and B) (Figure 11) (134–137). It is known that many common drugs such as warfarin, diazepam, and ibuprofen bind to one of the two primary sites (site 1 in subdomain IIA, site 2 in subdomain IIIA) (138). In fact, HSA helps to solubilize these compounds to achieve high concentration in the bloodstream; otherwise, they would easily aggregate and be poorly distributed.

In 1995, we found that tetrakis(*o*-pivalamido)phenylporphyrinatoiron bearing a covalently linked proximal imidazole (FeP1, Figure 12) was incorporated into HSA, yielding a red HSA-FeP1 hybrid (11). This synthetic hemoprotein can reversibly bind and release O₂ under physiological conditions (pH 7.4, 37 °C) in much the same way as Hb. The HSA host adsorbs a maximal eight FeP1 molecules. Their stepwise binding constants (*K*₁–*K*₈) range from 1.2 × 10⁶ to 1.2 × 10⁴ (M⁻¹) (Table




Figure 12. Structure of FePs in HSA-FePs.

3) (139, 140). Solution properties of the HSA-FeP1 solution ($[r\text{HSA}] = 5 \text{ wt } \%$, $\text{FeP}/\text{HSA} = 1-8$, mol/mol) are almost identical to those of HSA itself: the specific gravity, 1.013; viscosity, 1.1 cP; and COP, 20 Torr. Circular dichroism (CD) spectroscopy and isoelectric focusing measurement revealed that the second-order structure and surface charge distribution of HSA were unaltered after binding of FeP1. The obtained solution showed a long shelf-life of over two years at room temperature (141). Furthermore, HSA-FeP1 has no effect on the morphology of blood cell components (142) and does not engender immunological reaction and platelet activation (143). Upon addition of O_2 gas through this solution, the visible absorption spectrum immediately changed to that of the O_2 adduct complex. After exposure to CO gas, a stable carbonyl complex of HSA-FeP1 was formed (139, 140). The coordination structure of FeP1 and spin-state of the central ferrous ion was characterized by IR, resonance Raman, and magnetic circular dichroism (MCD) spectroscopy (139, 140, 144). The carbonyl HSA-FeP1 moved to the NO adduct complex after bubbling NO gas (145). Subsequent ESR spectroscopy revealed that FeP1 in albumin formed a six-coordinate nitrosyl complex. The proximal imidazole moiety does not dissociate from the central ferrous ion when NO binds to the trans site (146).

The $P_{50}(\text{O}_2)$ value of HSA-FeP1 is always constant (33 Torr, 37°C) independent of the binding number of FeP1 (eq 1, Table 5)

$$\text{HSA-FeP} + \text{L} \xrightleftharpoons[k_{\text{off}}(\text{L})]{k_{\text{on}}(\text{L})} \text{HSA-FeP(L)} \quad [\text{L}: \text{O}_2 \text{ or CO}]$$

$$K(\text{L}) = [P_{50}(\text{L})]^{-1} = k_{\text{on}}(\text{L})/k_{\text{off}}(\text{L}) \quad (1)$$

The O_2 binding equilibrium curve shows no cooperativity. However, the O_2 transporting efficiency between the lungs [$P(\text{O}_2)$: ca. 110 Torr] and muscle tissue [$P(\text{O}_2)$: ca. 40 Torr] is 22%, which is identical to that for RBC.

Table 5. Solution Properties and Characteristics of HSA-FeP1

| | |
|--------------------------------|--|
| binding number of FeP1 (n) | 1-8 |
| binding constant of FeP1 | $1.2 \times 10^6 - 1.2 \times 10^4 \text{ M}^{-1}$ |
| M_w | (66.5 + 1.3 n) kDa |
| pI | 4.8 |
| viscosity ^{a,b} | 1.1 cP |
| COP ^{a,b,c} | 20 Torr |
| shelf life ^{a,d} | >2 years |

^a In phosphate buffered solution (pH 7.3), [HSA]: 5 g/dL. ^b At 37°C . ^c A membrane filter with a cutoff (M_w , 30×10^3) was used. ^d At 25°C .

The O_2 association and dissociation rate constants [$k_{\text{on}}(\text{O}_2)$ and $k_{\text{off}}(\text{O}_2)$] can be measured using laser flash photolysis (147, 148). Interestingly, the rebinding process of O_2 to HSA-FeP1 included two phases (fast and slow phase), perhaps because of the different environment around each FeP1 in the protein (149). The $P_{50}(\text{O}_2)$ value can be controlled by tuning the chemical structure of FeP1. We have synthesized quantities of Fe(II)porphyrins (Figure 12) and evaluated the O_2 binding parameters of their HSA-FeP hybrids (Table 6).

Actually, FeP2 has a bulky 1-methylcyclohexanamide group on the porphyrin ring plane (150). The O_2 binding affinity of HSA-FeP2 [$P_{50}(\text{O}_2)$: 35 Torr] was almost identical to that of HSA-FeP1. However, the stability of the oxygenated complex increased to 4.5 times its usual value [half-life $\tau_{1/2}(\text{O}_2)$, 9 h; pH 7.3; 37°C] (150).

In general, the basicity and structure of the proximal base greatly influences the O_2 binding property of Fe^{2+} porphyrin. Both FeP3 and FeP4, similar analogues having an His ligand, showed high O_2 binding affinities [$P_{50}(\text{O}_2)$: 3 Torr] (Figure 13, Table 6). Kinetically, substitution of the 2-methylimidazole to His reduces the O_2 dissociation rate constant (150). Although one might think that high O_2 binding affinity is not useful as a blood substitute, it can be efficient for oxygenation of hypoxic

Table 6. O₂ Binding Properties of HSA-FePs in Phosphate Buffered Solution (pH 7.3, 25 °C)

| FeP | $k_{\text{on}}(\text{O}_2)$ ($\mu\text{M}^{-1} \text{s}^{-1}$) | | $k_{\text{off}}(\text{O}_2)$ (ms^{-1}) | | $P_{50}(\text{O}_2)^a$ (Torr) | refs |
|-----|--|------|---|--------|-------------------------------|---------------|
| | fast | slow | fast | slow | | |
| 1 | 34 | 9.5 | 0.75 | 0.20 | 13 (33) | 139, 149, 150 |
| 2 | 46 | 7.3 | 0.98 | 0.16 | 13 (35) | 150 |
| 3 | 36 | 6.1 | 0.059 | 0.010 | 1 (3) | 150 |
| 4 | 54 | 8.8 | 0.089 | 0.014 | 1 (3) | 150 |
| 5 | 54 | 6.8 | 0.02 | 0.0024 | 0.2 (1) | 151 |
| 6 | 54 | 8.1 | 0.62 | 0.093 | 7 (22) | 151 |
| 7 | 34 | 4.5 | 0.045 | 0.0059 | 0.8 (2) | 152 |
| 8 | 11 | 1.5 | 0.50 | 0.069 | 28 | 153 |
| 9 | 11 | 2.0 | 0.41 | 0.076 | 23 | 153 |
| 10 | 8.9 | 2.3 | 0.34 | 0.088 | 23 | 153 |
| 12 | 29 | 4.4 | 1.10 | 0.16 | 22 (45) | 154 |
| 13 | — | — | — | — | 0.1 | 155, 156 |
| 14 | — | — | — | — | 0.1 | 155, 156 |
| 15 | — | — | — | — | 0.4 | 156 |
| 16 | — | — | — | — | 0.1 | 155, 156 |
| 17 | 28 | — | 0.33 | — | 9 (27) | 157 |

^a At 37 °C in parentheses.




Figure 13. O₂ binding equilibrium curve of HSA-FePs under physiological conditions (pH 7.3, 37 °C).

regions in tumors. Furthermore, the HSA-FeP4 showed long $\tau_{1/2}(\text{O}_2)$ of 25 h (37 °C), which is 13-fold longer than that of HSA-FeP1.

Another HSA-FeP5, in which the active porphyrin has 3-methyl-L-histidine as a proximal base, exhibits an extraordinarily high O₂ binding affinity [$P_{50}(\text{O}_2)$: 1 Torr] that approaches those of relaxed-state Hb and Mb (151). It is remarkable that replacement of the 3-methyl-L-histidine moiety by 1-methyl-L-histidine isomer (HSA-FeP6) reduced O₂ binding affinity to 1/35th of its former level. The low O₂ affinity of FeP6 is predominantly reflected by the high $k_{\text{off}}(\text{O}_2)$ value. The axial Fe-N(1-methyl-L-histidine) coordination might be restrained by steric interaction between the 4-methylene group of the His ring and the porphyrin plane (151).

The proximal histidyl side chain can be introduced easily into the β -pyrrolic position of the porphyrin via an acyl bond in two steps, FeP7 (152). Although an electron-withdrawing acyl group is bound at the porphyrin periphery, the O₂ binding affinity of HSA-FeP7 is slightly higher than that of HSA-FeP4. The rigid His-Gly(carboxy)butanoyl spacer of FeP7 probably produces a favorable geometry to fix the imidazole onto the central Fe²⁺ of the porphyrin.

Double-sided porphyrins (FeP8, FeP9, and FeP10) were also incorporated into HSA (153). We expected that steric encumbrances on both sides of the porphyrin enable the HSA-FePs to form a stable O₂ adduct complex. Actually, the $\tau_{1/2}(\text{O}_2)$ of HSA-FeP8 was 5 h, which is 2.5-fold longer than that of HSA-FeP1. In addition, HSA-FeP8 showed high stability against hydrogen


peroxide. The HSA incorporating double-sided porphyrins would be useful for the synthetic analogue of the oxidation enzyme.

Tailed porphyrins having an $\alpha,\alpha,\alpha,\beta$ -conformer, FeP11 and FeP12, were synthesized easily via four steps from atropisomers of tetrakis(*o*-aminophenyl)porphyrin relative to eight steps of FeP1 (154). Although HSA-FeP12 binds O₂ reversibly, HSA-FeP11 was quickly oxidized by O₂. We concluded that the 1-methylcyclohexanamide groups are necessary for the tailed porphyrin to form an O₂ adduct complex under physiological conditions.

Investigations have also revealed that heme [Fe²⁺-toporphyrin IX; protoheme] derivatives having a proximal base at the propionate side chain (FeP13–FeP16) were incorporated into HSA (155, 156). The oxidation process of HSA-FeP13(O₂) to the inactive ferric state obeyed first-order kinetics, suggesting that the μ -oxo dimer formation was prevented by the immobilization of FeP13 into albumin. In fact, HSA-FeP15 showed lower O₂ binding affinity [high $P_{50}(\text{O}_2)$] than the others did. The acetyl groups at the 3,8-positions of FeP15 decrease the electron density of the porphyrin macrocycle, thereby reducing the O₂ binding affinity. Actually, HSA-FeP16, in which the His-Gly tail coordinates to the Fe²⁺ center, showed the most stable O₂ adduct complexes [$\tau_{1/2}(\text{O}_2)$, 90 min; pH 7.3; 25 °C] of any of these heme compounds.

3.2. Surface-Modified HSA-FeP with PEG. A remaining defect of HSA-FeP is that the active Fe²⁺ porphyrin sites dissociate slowly from HSA when infused into animals because FeP is bound noncovalently to albumin. One possible solution is to bind the FeP molecule covalently to the protein. We have synthesized FeP17 having a succinimide side chain; it can react with the Lys amino group of HSA (157). The O₂ binding property of HSA-FeP17 is almost identical to that of HSA-FeP1.

Another approach is surface modification with PEG. Actually, PEG decollations of proteins and liposomes are well-known to enhance their plasma half-life, thermostability, nonimmunogenicity, and solubility in organic solvents (158–163). We surmised that surface modification of HSA-FeP2 by PEG might help to prolong the circulation lifetime of FeP2 and retain its O₂ transporting ability in vivo for a long period. Consequently, HSA-FeP2 (FeP2/HSA = 4/1, mol/mol) was modified with maleimide-PEG, and the solution properties, O₂ binding behavior, and circulatory persistence of the PEG-modified HSA-FeP2 [PEG(HSA-FeP2)] were examined (164). A thiolation reagent, iminothiolane, first reacted with the Lys amino groups of HSA to create active thiols that bind to α -maleimide- ω -methoxy PEG (Figure 14a). Mass spectroscopy measurements and quantification of the mercapto group of PEG(HSA-FeP2)



a) In phosphate buffered solution ([HSA]: 5g/dL, PEG_{M_n}/HSA-FeP2 = 6, mol/mol) in average, pH 7.3, 37°C.

Figure 14. Surface modification of HSA-FeP with poly(ethylene glycol). (a) Synthetic scheme of PEG_{M_n}(HSA-FeP2). (b) Solution and O₂ binding properties. (c) Persistence of FeP2 in serum after administration of PEG_{M_n}(HSA-FeP2) into Wistar rats. Each value represents the mean ± SD of four rats.

revealed the conjugation of six PEG chains on the HSA-FeP2 surface. The initial FeP2/HSA ratio 4/1 (mol/mol) was unchanged after the PEG binding. The adjustment of viscosity is important to design an artificial O₂ carrier. Maintenance of viscosity is necessary to preserve shear stress on the vascular wall that prevents loss of the functional capillary density (123, 165). The viscosity and COP of PEG(HSA-FeP2) were modulated to some degree by changing the molecular weight of PEG [M_w: 2 × 10³ (PEG_{M₂}) and 5 × 10³ (PEG_{M₅})] (Figure 14b). In fact, PEG_{M₂}(HSA-FeP2) showed almost identical values of viscosity and COP to those of the nonmodified HSA-FeP2. In contrast, PEG_{M₅}(HSA-FeP2) showed a higher viscosity and more pronounced hyperoncotic property relative to those of HSA-FeP2. Nevertheless, PEG_{M₅} conjugate may be useful as an efficient plasma expander (118, 166).

Under physiological conditions, PEG_{M_n}(HSA-FeP2) binds and releases O₂. The P₅₀(O₂) values were almost identical to those of the original HSA-FeP2, indicating that the O₂ binding equilibrium was not influenced by the presence of the PEG chains (Figure 14b). Surface modification by PEG delays proton-driven oxidation of the O₂ adduct complex, giving HSA-FeP2 the τ_{1/2}(O₂) of 12 h, which is almost equal to that of a natural hemoprotein, Mb [τ_{1/2}(O₂), 12 h; pH 7, 35 °C] (167). The conjugated PEG might change the local proton concentration of the HSA interior compared to the outer aqueous solution.

The circulation persistence of FeP2 in the bloodstream was measured after administration of PEG_{M_n}(HSA-FeP2) to anesthetized rats (164). The PEG_{M_n}(HSA-FeP2) solution (20% volume of the circulatory blood) was injected intravenously into rats from the tail vein. The concentration decays of PEG_{M_n}(HSA-FeP2) in the blood showed single exponentials with half-life [τ_{1/2}(FeP2)] of 13–16 h (Figure 14c). These values are considerably longer than those of the corresponding nonmodified HSA-FeP2 (168). Surface modification of HSA-FeP2 by PEG prevented the rapid clearance of the incorporated FeP2. On the basis of these findings, we can conclude that surface modification of HSA-FeP2 by PEG comprehensively improved its O₂ transporting ability.

We then proceeded to evaluate physiological responses to an exchange transfusion with PEG_{M₂}(HSA-FeP2) in an acute anemia rat model (169) (Figure 15). The animals were first placed in a 65 vol % hemodilution with 5 g/dL HSA. They subsequently underwent a 30 vol % blood replacement with the PEG_{M₂}(HSA-FeP2) solution. As negative and positive control groups, a 5 g/dL HSA solution (HSA group) and washed RBC suspension (RBC group) were infused, respectively, to similarly operated rats in hemorrhage. The isovolemic 65% hemodilution with HSA reduced the Hb concentration, thereby decreasing the O₂ supply to the tissue. Consequently, the mean arterial pressure (MAP), renal cortical O₂ partial pressure [PtO₂(R)], and O₂ partial pressure of muscle tissue [PtO₂(M)] were decreased. During hemorrhagic shock by 30% bleeding, significant decreases in the MAP, venous O₂ pressure (PvO₂), PtO₂(R), and PtO₂(M) were observed by the loss of the circulation blood volume. The heart rate (HR) and respiration rate were also decreased. In contrast, arterial O₂ pressure (PaO₂) increased to about 160% of the basal value (b.v.). The arterial CO₂ pressure (PaCO₂) decreased to about 62% of the b.v.; the pH increased to 7.55.

The injection of the sample solutions increased the blood volume and improved the circulatory flow. Lactate was washed out from the tissues and into the circulatory system, which decreased the pH to the initial level of 7.43 in all groups. The administration of HSA restored no parameters: death occurred within 41 min. In contrast, the infusion of PEG_{M₂}(HSA-FeP2) or RBC kept all the rats alive until the end of measurements. After injection of PEG_{M₂}(HSA-FeP2), the animals showed marked and rapid recovery in MAP, HR, PaO₂, PvO₂, PaCO₂, and pH, resembling that shown in the RBC group. These results demonstrate the O₂ transporting capability of the PEG_{M₂}(HSA-FeP2) solution as a resuscitative fluid. We observed that albumin-based oxygen carrier does not induce hypertensive action, because of its low permeability through the vascular endothelium in comparison with that of Hb molecules. The heart rate responses after the injection were also negligibly small. Visualization of the intestinal microcirculatory changes clearly




Figure 15. Effect of PEG_{M2}(HSA-FeP2) solutions on (a) MAP, (b) HR, (c) PaO₂, (d) PvO₂, (e) PtO₂(R), (f) PtO₂(M), (g) PaCO₂, and (h) pH in anesthetized rats subjected to hemodilution and hemorrhage. Each value represents the mean \pm SD of five rats [red, PEG_{M2}(HSA-FeP2) group; blue, washed RBC group; and black, HSA group]. Arrows (1), (2), and (3), respectively, indicate the periods of 65% hemodilution, 30% bleeding, and sample infusion. ^a*p* < 0.05 versus HSA group (Tukey-Kramer test), ^b*p* < 0.05 versus PEG_{M2}(HSA-FeP2) group (unpaired *t*-test), and ^c*p* < 0.05 versus PEG_{M2}(HSA-FeP2) group (Tukey-Kramer test).




Figure 16. The solid membrane of PEG_{M2}(HSA-FeP2). (a) Photograph of the membrane on the glass, (b) SEM of the membrane section, (c) photograph of the flexible film peeled from the poly(styrene) dish, and (d) SEM of the isolated film.

revealed the widths of the venule and arteriole to be fairly constant (170).

Reversible oxygenation of PEG_{M2}(HSA-FeP2) was observed even in the solid state (171). The aqueous solution of PEG_{M2}(HSA-FeP2)(CO) complex was spread on the glass plate and dried overnight at room temperature, producing a red transparent solid membrane (Figure 16a). In contrast, HSA-FeP2 without PEG decolored yielded a brittle membrane with many cracks. Scanning electron microscopy (SEM) observations of the PEG_{M2}(HSA-FeP2) membrane showed a uniform thickness of 15 μ m and a smooth surface (Figure 16b). The $\tau_{1/2}(\text{O}_2)$ was 40 h, which is three times longer than the value in water. The O₂ binding affinity was about a half that of the monomeric PEG_{M2}(HSA-FeP2).


We subsequently added hyaluronic acid (HA) as a supporting polymer to the protein solution and prepared the solid membrane

on a poly(styrene) dish. Actually, HA is known as a glycosaminoglycan component of connective tissues, hyaline bodies, and extracellular matrix (172). Water evaporation of the PEG_{M2}(HSA-FeP2)/HA mixture ([HSA]: 2.5 wt % and [HA]: 0.2 wt %) produced a uniform red solid membrane that was easily peeled from the dish, yielding a free-standing homogeneous thin film of the PEG(HSA-FeP2)/HA hybrid (Figure 16c,d).

The PEG_{M2}(HSA-FeP2) solution is useful as a valuable O₂-carrying plasma. Membranes of PEG_{M2}(HSA-FeP2) with micrometer thickness can serve as a RBC substitute that can be preserved anywhere and reproduced as a saline solution at any time.

3.3. Recombinant HSA-Heme (rHSA-Heme) Prepared Using Site-Directed Mutagenesis. Hemin [Fe³⁺ protoporphyrin IX] released from methb during enucleation of RBC or through hemolysis is captured by HSA with a high binding constant ($K \approx 10^8 \text{ M}^{-1}$) (173). Crystallographic studies have revealed that heme is bound within a narrow D-shaped hydrophobic cavity in subdomain IB with axial coordination of Tyr-161 to the central ferric ion and electrostatic interactions between the porphyrin propionates and a triad of basic amino acid residues (Arg-114, His-146, and Lys-190) (Figure 17) (174, 175). In terms of the general hydrophobicity of this α -helical heme pocket, the subdomain IB of HSA potentially has similar features to the heme binding site of Hb or Mb. However, when one reduces HSA-hemin to obtain the ferrous complex, it is autoxidized rapidly by O₂, even at low temperature ($\sim 0^\circ \text{C}$), because HSA lacks the proximal His, which, in Hb and Mb, enables the prosthetic heme group to bind O₂. Knowledge of the detailed architecture of the heme binding site in HSA enables us to design mutagenesis experiments to construct a tailor-made heme pocket for stable O₂ binding. Therefore, we used site-directed mutagenesis to introduce an His into the heme binding site that was expected to provide axial coordination to the central Fe²⁺ atom of the heme and thereby promote O₂ binding.

Results of our modeling experiments suggested that a favorable position for the axial imidazole insertion would be Ile-142 (Figure 17). The N_i(His)-Fe distances were estimated



| rHSA-heme | Position | | | | |
|------------------|------------|------------|-----|------------|------------|
| | 142 | 161 | 182 | 185 | 186 |
| Wild type | Ile | Tyr | Leu | Leu | Arg |
| I142H | His | Tyr | Leu | Leu | Arg |
| I142H/Y161L (HL) | His | Leu | Leu | Leu | Arg |
| I142H/Y161F (HF) | His | Phe | Leu | Leu | Arg |
| HL/L185N | His | Leu | Leu | Asn | Arg |
| HF/L185N | His | Phe | Leu | Asn | Arg |
| HL/L185Q | His | Leu | Leu | Gln | Arg |
| HF/L185Q | His | Phe | Leu | Gln | Arg |
| HF/L185H | His | Phe | Leu | His | Arg |
| HL/R186L | His | Leu | Leu | Leu | Leu |
| HL/R186F | His | Leu | Leu | Leu | Phe |

Figure 17. (a) Crystal structure of HSA-hemin complex (1O9X) from ref 174. Hemin is shown in a space-filling representation. (b) Heme pocket structure in subdomain 1B and positions of amino acids where site-specific mutations were introduced. Abbreviations of rHSA(mutants) are shown in the table.

as 2.31 Å for I142 (compared to 2.18 Å for Mb). We therefore designed and produced two single mutants I142H and a double mutant I142H/Y161L (HL) (176).

In the UV-vis absorption spectrum of rHSA(HL)-hemin, the ligand-to-metal charge transfer band at 625 nm was weakened because of the Y161L mutation. The MCD spectrum of rHSA(HL)-hemin showed a similar S-shaped pattern in the Soret band region resembling that of ferric Mb (177, 178). These results suggest that rHSA(HL)-hemin is in a predominantly ferric high-spin complex having a water molecule as the sixth ligand. The rHSA-hemin was easily reduced to the ferrous complex by adding a small molar excess of aqueous sodium dithionite under an Ar atmosphere (Figure 18). A single broad absorption band (λ_{max} : 559 nm) in the visible absorption spectrum and the MCD spectrum of rHSA(HL)-heme indicated the formation of a five-N-coordinate high-spin complex (176, 177, 179). The heme therefore appears to be accommodated in the mutated heme pocket with an axial coordination involving His-142. Upon exposure of rHSA(HL)-heme solution to O_2 , the UV-vis absorption changed immediately to that of the O_2 adduct complex (Figure 18). It formed a carbonyl complex under a CO atmosphere. The single mutant rHSA(I142H)-heme, which retains Y161, was unable to bind O_2 . The polar phenolate residue at the top of the porphyrin plane is likely to accelerate the proton-driven oxidation of the Fe^{2+} center. The replacement of Tyr-161 in rHSA(I142H)-heme by Leu enhanced stabilization of the O_2 adduct complex.

To evaluate the kinetics of O_2 and CO bindings to rHSA-hemes, laser flash photolysis experiments were carried out (Tables 7 and 8). It is noteworthy that the absorbance decay accompanying the CO recombination to rHSA(HL)-heme was composed of double-exponential profiles, which is normally not observed in Mb (the faster phase is defined as species I; the slower phase is defined as species II). The ratio of the amplitude of the species I and the species II was approximately 3:2. On the other hand, the rebinding of O_2 to rHSA(HL)-heme followed a simple monophasic decay. Numerous investigations of syn-




Figure 18. UV-vis absorption spectral changes of rHSA(HL)-heme in potassium phosphate buffered solution (pH 7.0).

thetic model hemes have helped to reveal the relation between the structure around the hemes and their O_2 and CO binding abilities (4, 147, 148). A bending strain in the proximal base coordination to the central Fe^{2+} atom, the "proximal-side steric (proximal pull) effect", is known to be capable of both increasing the dissociation rate for CO and decreasing the association rate. Simultaneously, it increases the O_2 dissociation rate without greatly altering the O_2 association kinetics. Consequently, one possible explanation for the existence of the two phases is that two different geometries of the axial His (His-142) coordination to the central ferrous ion of the heme might exist, each one accounting for a component of the biphasic kinetics of CO rebinding.

Table 7. O₂ Binding Parameters of rHSA(Mutant)-Heme Complexes in Phosphate Buffered Solution (pH 7.0) at 22 °C

| hemoproteins | $k_{on}(O_2)$ ($\mu M^{-1} s^{-1}$) | $k_{off}(O_2)$ (m s ⁻¹) | | $P_{50}(O_2)$ (Torr) | |
|---------------------|--|-------------------------------------|------|----------------------|-----|
| | | I | II | I | II |
| rHSA(HL)-heme | 7.5 | 0.22 | 1.70 | 18 | 134 |
| rHSA(HF)-heme | 20 | 0.10 | 0.99 | 3 | 31 |
| rHSA(HL/L185N)-heme | 14 | 0.02 | 0.29 | 1 | 14 |
| rHSA(HF/L185N)-heme | 26 | 0.10 | 1.03 | 2 | 24 |
| rHSA(HL/R186L)-heme | 25 | 0.41 | 8.59 | 10 | 209 |
| rHSA(HL/R186F)-heme | 21 | 0.29 | 7.01 | 9 | 203 |
| Mb ^a | 14 | 0.012 | | 0.51 | |
| RBC ^b | | | | 8 | |

^a Sperm whale myoglobin in 0.1 M potassium phosphate buffer (pH 7.0, 20 °C); ref 180. ^b Human red cell suspension in isotonic buffer (pH 7.4, 20 °C); ref 181.

Table 8. CO Binding Parameters of rHSA(Mutant)-Heme Complexes in Phosphate Buffered Solution (pH 7.0) at 22 °C

| hemoproteins | $k_{on}(CO)$ ($\mu M^{-1} s^{-1}$) | | $k_{off}(CO)$ (s ⁻¹) | | $P_{50}(CO)$ (Torr) | |
|---------------------|--------------------------------------|------|----------------------------------|-------|---------------------|-------|
| | I | II | I | II | I | II |
| rHSA(HL)-heme | 2.0 | 0.27 | 0.013 | 0.079 | 0.0053 | 0.240 |
| rHSA(HF)-heme | 6.8 | 0.72 | 0.009 | 0.061 | 0.0011 | 0.068 |
| rHSA(HL/L185N)-heme | 6.8 | 1.60 | 0.008 | 0.039 | 0.0010 | 0.020 |
| rHSA(HF/L185N)-heme | 7.7 | 1.09 | 0.008 | 0.043 | 0.0008 | 0.032 |
| rHSA(HL/R186L)-heme | 5.0 | 0.57 | 0.011 | 0.165 | 0.0018 | 0.234 |
| rHSA(HL/R186F)-heme | 7.9 | 1.12 | 0.010 | 0.148 | 0.0010 | 0.107 |
| Mb ^a | 0.51 | | 0.019 | | 0.03 | |

^a Sperm whale myoglobin in 0.1 M potassium phosphate buffer (pH 7.0, 20 °C); ref 180.

3.4. Modulation of O₂ Binding Property of rHSA-(mutant)-Heme.

To control the O₂ binding affinity of rHSA-heme, we designed and produced diverse rHSA(mutant)-hemes in which bulky hydrophobic or hydrophilic amino acids were introduced around the O₂ binding site (Tyr-161, Leu-182, Leu-185, and Arg-186) (Figure 17). More recently, the beneficial effect of low-dose CO on the microcirculation by a hemoglobin-based artificial oxygen carrier has been discussed (132, 182). Control of the CO binding affinity of rHSA-heme is also tempting.

A. Substitution of Tyr-161 with Leu or Phe. The first, Tyr-161, was substituted to noncoordinating and hydrophobic amino acids (Leu or Phe). The O₂ and CO binding properties of rHSA(HL)-heme and rHSA(I142H/Y161F)-heme [rHSA(HF)-heme] showed that the presence of a Phe rather than a Leu at position 161 results in 6-fold and 4-fold increases in the O₂ binding affinity for species I and II, respectively (Table 7). This enhancement is mainly attributable to an increase in the O₂ association rate constant. The same trend was observed for CO binding [3-fold increase in $k_{on}(CO)$] (Table 8). The substitution of Leu-161 (102 Å³) by Phe-161 (137 Å³) (183) replaces an isopropyl group with a rigid benzyl group within the heme pocket. In rHSA(HL), the small side chain of Leu-161 might enable free rotation of the side chain of neighboring Leu-185, thereby reducing the volume on the distal side of the porphyrin plane (Figure 19a,b). On the other hand, the bulkier aromatic side chain of Phe-161 might prevent rotation of the isopropyl group of Leu-185 and thereby provide greater room of the distal pocket; this effect might provide easier access to the heme Fe²⁺ atom and account for the increased association rates for O₂ and CO.

B. Substitution of Leu-185 with Polar Amino Acid. Leu-185 was substituted with a more hydrophilic amino acid (Asn, Gln, or His), which was expected to interact with the coordinated O₂ by hydrogen bond and to stabilize the O₂ adduct complex similarly to Hb and Mb. In rHSA(mutant)-hemes in which Gln




Figure 19. The proposed configuration of Leu-185 in (a) rHSA(HL)-heme and (b) rHSA(HF)-heme, Asn-185 in (c) rHSA(HL/L185N)-heme and (d) rHSA(HF/L185N)-heme, and Leu-186 in (e) rHSA(HL/R186L)-heme.

or His was introduced into Leu-185, they formed ferrous six-coordinated low-spin complexes under an Ar atmosphere. That result suggests that the introduced amino acid coordinates to the heme iron as a sixth ligand under an Ar atmosphere. Upon exposure of the solutions to O₂, they were oxidized. Bis-histidyl hemochromes are known to be oxidized by O₂ rapidly via an outer sphere mechanism (184–186). On the other hand, rHSA(HL/L185N)-heme and rHSA(HF/L185N)-heme in which Asn was introduced at Leu-185 formed ferrous five-coordinated high-spin complexes under an Ar atmosphere. They formed O₂ adduct complexes under O₂ atmosphere. The introduced Asn is estimated to be too far to coordinate to the heme.

Marked differences were apparent in a comparison of the O₂ and CO binding parameters for rHSA(HL)-heme and rHSA(HL/L185N)-heme. First, the presence of Asn rather than Leu at position 185 caused 2-fold and 3–6-fold increases, respectively, in the $k_{on}(O_2)$ and $k_{on}(CO)$ values. The Asn might partly rotate upward, which provides somewhat greater space of the distal pocket. Second, Asn-185 induced 18-fold and 10-fold increases in the O₂ binding affinity for species I and II, because the $k_{off}(O_2)$ values were 1/6–1/11 of their former values. This corresponds to a free energy difference of -1.8 kcal mol⁻¹ at 22 °C. The magnitude of the effect seems to be reasonable considering that, in HbO₂ and MbO₂, the distal His-64 stabilizes the coordinated O₂ by -0.6 to -1.4 kcal mol⁻¹ because of the hydrogen bond (187). In contrast, The O₂ and CO binding parameters for rHSA(HF)-heme and rHSA(HF/L185N)-heme showed no significant differences. The bulky benzyl side chain of Phe-161 can prevent rotation of the polar amide group of Asn-185 and thereby decrease the effect of polarity and size on O₂ and CO binding parameters (Figure 19c,d) (188).

C. *Substitution of Arg-186 with Leu or Phe.* For administration into the human circulatory system, it would be better if the affinity were similar to the human RBC [$P_{50}(O_2)$: 8 Torr, 25 °C]. It is expected that providing a certain degree of hydrophobicity into the distal side of the heme by insertion of a nonpolar residue would reduce the O_2 binding affinity of the rHSA-heme complex. The most suitable position for that introduction might be at Arg-186, which is the entrance of the heme pocket and which is rather close to the central Fe(II) ion. Therefore, rHSA(HL/R186L)-hemin and rHSA(HL/R186F)-hemin were prepared. The O_2 dissociation rate constants of rHSA(HL/R186L)-heme and rHSA(HL/R186F)-heme were 3–4-fold higher than that of rHSA(HF)-heme, which reduced the O_2 binding affinities [larger $P_{50}(O_2)$]. This reduction might be attributable to the increased hydrophobicity in the distal pocket. The O_2 binding affinities of rHSA(HL/R186L)-heme [$P_{50}(O_2)$: 10 Torr] and rHSA(HL/R186F)-heme [$P_{50}(O_2)$: 9 Torr] have become equivalent to those of human RBC. The important structural factor in these mutants is Y161L, which enables the rotation of the isopropyl group of Leu-185 above the O_2 coordination site. Unexpectedly, the $k_{on}(O_2)$ and $k_{on}(CO)$ values of rHSA(HL/R186L)-heme and rHSA(HL/R186F)-heme were 3-fold and 3–4-fold higher than those of rHSA(HL)-heme and in the same range as that of rHSA(HF)-heme. In fact, Leu-161 is small, but the hydrophobic Leu-186 or Phe-186 might be integrated into the heme pocket from the entrance and might push up the neighboring Leu-185 residue (Figure 19e) (188).

We have engineered mutant rHSA-heme complexes that can bind O_2 . Principal modifications to the heme pocket that are necessary to confer reversible O_2 binding are (i) replacement of Tyr-161 by hydrophobic amino acid (Leu or Phe), and (ii) introduction of His as a proximal base at position Ile-142. Furthermore, (iii) modification of the distal amino acid has a considerable effect on the modulation of O_2 and CO binding affinities.

4. CONCLUSIONS

The structures of our artificial O_2 carriers differ greatly from those of sophisticated RBCs. However, clear advantages of simplified artificial O_2 carriers are readily apparent: the absence of blood-type antigens and infectious viruses, stability for long-term storage at room temperature for any emergency, all of which overwhelm the functionality of RBCs. The shorter half-life of artificial O_2 carriers in the bloodstream (ca. 3 days) limits their use, but they are applicable as a transfusion alternative for shorter periods of use. Easy manipulation of physicochemical properties such as $P_{50}(O_2)$ and viscosity supports their possible development of tailor-made O_2 carriers to suit various clinical indications. The achievements of ongoing research described above give us confidence in advancing the further development with the expectation of its eventual realization.

ACKNOWLEDGMENT

The authors gratefully acknowledge Prof. H. Nishide, Prof. S. Takeoka (Waseda Univ.), Prof. R. Yozu, Prof. M. Suematsu, Dr. H. Horinouchi, Dr. M. Watanabe, Dr. E. Ikeda, Dr. Y. Izumi, Dr. M. Yamamoto, Dr. T. Ikeda (Keio Univ.), Dr. H. Ikeda, Dr. H. Azuma, Dr. M. Fujiwara, Dr. H. Abe (Hokkaido Red Cross Blood Center), Dr. M. Takaori (East Takarazuka Satoh Hospital), Prof. M. Otagiri (Kumamoto Univ.), Prof. M. Intaglietta (Univ. of California, San Diego), Prof. W. T. Phillips (Univ. of Texas, San Antonio), Prof. D. Ermi (Inselspital Hospital, Univ. of Berne), Prof. M. Okamoto (Weill Med. College, Cornell Univ.), Prof. S. Curry (Imperial College London) and their active colleagues for meaningful discussions and contributions to this research. This work was partly

supported by Health Sciences Research Grants (Research on Regulatory Science) from the Ministry of Health, Labour and Welfare, Japan, and Grant-in-Aid for Scientific Research from JSPS. The authors are the holders of patents related to the production and utilization of HbV and albumin-hemes.

LITERATURE CITED

- Perutz, M. F. (1970) Stereochemistry of cooperative effects in haemoglobin. *Nature* 228, 726–739.
- Jones, R. D., Summerville, A., and Basolo, F. (1979) Synthetic oxygen carriers related to biological systems. *Chem. Rev.* 79, 139–179.
- Collman, J. P. (1977) Synthetic model for the oxygen-binding hemoproteins. *Acc. Chem. Res.* 10, 265–272.
- Momenteau, M., and Reed, C. (1994) Synthetic heme dioxygen complexes. *Chem. Rev.* 94, 659–698.
- Collman, J. P., Gagne, R. R., Halbert, T. R., Marchon, J.-C., and Reed, C. A. (1973) Reversible oxygen adduct formation in ferrous complexes derived from "picket fence" porphyrins. A model for oxyhemoglobin. *J. Am. Chem. Soc.* 73, 7868–7870.
- Collman, J. P., Gagne, R. R., Reed, C. A., Halbert, T. R., Lang, G., and Robinson, W. T. (1975) "Picket fence porphyrins." Synthetic models for oxygen binding hemoproteins. *J. Am. Chem. Soc.* 97, 1427–1439.
- Matsushita, Y., Hasegawa, E., Eshima, K., and Tsuchida, E. (1983) Synthesis of amphiphilic porphyrinatoiron complexes having phosphocholine groups. *Chem. Lett.* 1983, 1387–1389.
- Tsuchida, E. (1985) Liposome-embedded iron-porphyrins as an artificial oxygen carrier. *Ann. N.Y. Acad. Sci.* 446, 429–442.
- Tsuchida, E., and Nishide, H. (1986) Hemoglobin model - artificial oxygen carrier composed of porphyrinatoiron complexes. *Top. Curr. Chem.* 1132, 63–99.
- Komatsu, T., Moritake, M., Nakagawa, A., and Tsuchida, E. (2002) Self-organized lipid-porphyrin bilayer membranes in vesicular form: nanostructure, photophysical properties and dioxygen coordination. *Chem. Eur. J.* 8, 5469–5480.
- Komatsu, T., Ando, K., Kawai, N., Nishide, H., and Tsuchida, E. (1995) O_2 -transport albumin - a new hybrid hemoprotein incorporating tetraphenylporphyrinatoiron(II). *Chem. Lett.* 813–814.
- Savitsky, J. P., Doczi, J., Black, J., and Arnold, J. D. (1978) A clinical safety trial of stroma-free hemoglobin. *Clin. Pharm. Ther.* 23, 73–80.
- Greenwald, R. B., Pendri, A., Martinez, A., Gilbert, C., and Bradley, P. (1996) PEG thiazolidine-2-thione, a novel reagent for facile protein modification: conjugation of bovine hemoglobin. *Bioconjugate Chem.* 7, 638–641.
- Kluger, R., and Li, X. (1997) Efficient chemical introduction of a disulfide cross-link and conjugation site into human hemoglobin at β -lysine-82 utilizing a bifunctional aminoacyl phosphate. *Bioconjugate Chem.* 8, 921–926.
- Sakai, H., Yuasa, M., Onuma, H., Takeoka, S., and Tsuchida, E. (2000) Synthesis and physicochemical characterization of a series of hemoglobin-based oxygen carriers: objective comparison between cellular and acellular types. *Bioconjugate Chem.* 11, 56–64.
- Hai, T. T., Pereira, D. E., Nelson, D. J., Catarello, J., and Srnak, A. (2000) Surface modification of diaspirin cross-linked hemoglobin (DCLHb) with chondroitin-4-sulfate derivatives. Part 1. *Bioconjugate Chem.* 11, 705–713.
- Manjula, B. N., Tsai, A., Upadhyay, R., Perumalsamy, K., Smith, P. K., Malavalli, A., Vandegriff, K., Winslow, R. M., Intaglietta, M., Prabhakaran, M., Friedman, J. M., and Acharya, A. S. (2003) Site-specific PEGylation of hemoglobin at Cys-93(β): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. *Bioconjugate Chem.* 14, 464–472.
- Murray, J. A., Ledlow, A., Launsbach, J., Evans, D., Loveday, M., and Conklin, J. L. (1995) The effects of recombinant human

- hemoglobin on esophageal motor function in humans. *Gastroenterology* 109:1241-1248.
- (19) Chatterjee, R., Welty, E. V., Walder, R. Y., Pruitt, S. L., Rogers, S. L., Arnone, A., and Walder, J. A. (1986) Isolation and characterization of a new hemoglobin derivative cross-linked between the α chains (lysine 99 α_1 \gg lysine 99 α_2). *J. Biol. Chem.* 261, 9929-9937.
- (20) Iwashita, Y. (1991) Pyridoxalated hemoglobin-polyoxyethylene conjugate (PHP) as an O₂ carrier. *Artif. Organs Today* 1, 89-114.
- (21) Riess, J. G. (2001) Oxygen carriers ("blood substitutes") - raison d'être, chemistry, and some physiology. *Chem. Rev.* 101, 2797-2920.
- (22) de Figueiredo, L. F., Mathru, M., Solanki, D., Macdonald, V. W., Hess, J., and Kramer, G. C. (1997) Pulmonary hypertension and systemic vasoconstriction might offset the benefits of acellular hemoglobin blood substitutes. *J. Trauma* 42, 847-854.
- (23) Tsai, A. G., Kerger, H., and Intaglietta, M. (1995) Microcirculatory consequences of blood substitution with $\alpha\alpha$ -hemoglobin. In *Blood Substitutes: Physiological Basis of Efficacy* (Winslow, R. M., Vandegriff, K., Intaglietta, M., Eds.) pp155-174, Birkhauser, Boston.
- (24) Goda, N., Suzuki, K., Naito, M., Takeoka, S., Tsuchida, E., Ishimura, Y., Tamatani, T., and Suematsu, M. (1998) Distribution of heme oxygenase isoforms in rat liver. Topographic basis for carbon monoxide-mediated microvascular relaxation. *J. Clin. Invest.* 101, 604-612.
- (25) Sakai, H., Hara, H., Yuasa, M., Tsai, A. G., Takeoka, S., Tsuchida, E., and Intaglietta, M. (2000) Molecular dimensions of Hb-based O₂ carriers determine constriction of resistance arteries and hypertension. *Am. J. Physiol. Heart Circ. Physiol.* 279, H908-H915.
- (26) Burhop, K., Gordon, D., and Estep, T. (2004) Review of hemoglobin-induced myocardial lesions. *Artif. Cells Blood Substit. Immobil. Biotechnol.* 32, 353-374.
- (27) Neragi-Miandoab, S., and Vlahakes, G. J. (2006) Elevated troponin I level with hemoglobin based oxygen carrying solutions (HBOCs) as a priming solution despite improved left ventricular function. *Interact. Cardiovasc. Thorac. Surg.* 5, 135-138.
- (28) Natanson, C., Kern, S. J., Lurie, P., Banks, S. M., and Wolfe, S. M. (2008) Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. *JAMA* 299, 2304-2312.
- (29) Balla, J., Jacob, H. S., Balla, G., Nath, K., Eaton, J. W., and Vercellotti, G. M. (1993) Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. *Proc. Natl. Acad. Sci. U.S.A.* 90, 9285-9289.
- (30) Sakai, H., Sato, A., Masuda, K., Takeoka, S., and Tsuchida, E. (2008) Encapsulation of concentrated hemoglobin solution in phospholipid vesicles retards the reaction with NO, but not CO, by intracellular diffusion barrier. *J. Biol. Chem.* 283, 1508-1517.
- (31) Sakai, H., Sato, A., Sobolewski, P., Takeoka, S., Frangos, J. A., Kobayashi, K., Intaglietta, M., and Tsuchida, E. (2008) NO and CO binding profiles of hemoglobin vesicles as artificial oxygen carriers. *Biochim. Biophys. Acta* 1784, 1441-1447.
- (32) Martini, J., Cabrales, P., Tsai, A. G., and Intaglietta, M. (2006) Mechanotransduction and the homeostatic significance of maintaining blood viscosity in hypotension, hypertension and haemorrhage. *J. Intern. Med.* 259, 364-372.
- (33) Sakai, H., Suzuki, Y., Kinoshita, M., Takeoka, S., Maeda, N., and Tsuchida, E. (2003) O₂ release from Hb vesicles evaluated using an artificial, narrow O₂-permeable tube: comparison with RBCs and acellular Hbs. *Am. J. Physiol. Heart Circ. Physiol.* 285, H2543-H2555.
- (34) Vandegriff, K. D., and Olson, J. S. (1984) The kinetics of O₂ release by human red blood cells in the presence of external sodium dithionite. *J. Biol. Chem.* 259, 12609-12618.
- (35) Chang, T. M. S. (2005) Therapeutic applications of polymeric artificial cells. *Nat. Rev. Drug Discov.* 4, 221-235.
- (36) Toyoda, T. (1965) Artificial blood. *Kagaku* 35, 7-13 (in Japanese).
- (37) Kimoto, S., Hori, M., Toyoda, T., and Sekiguchi, W. (1968) Artificial red cells. *Gekachiryō (Surgical Therapy)* 19, 324-332 (in Japanese).
- (38) Bangham, A. D., and Horne, R. W. (1964) Negative staining of phospholipids and their structure modification by surface-active agents as observed in the electron microscope. *J. Mol. Biol.* 8, 660-668.
- (39) Bangham, A. D., Standish, M. M., and Watkins, J. C. (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. *J. Mol. Biol.* 13, 238-252.
- (40) Djordjević, L., and Miller, I. F. (1977) Lipid encapsulated hemoglobin as a synthetic erythrocyte. *Fed. Proc.* 36, 567-571.
- (41) Farmer, M. C., Rudolph, A. S., Vandegriff, K. D., Hayre, M. D., Bayne, S. A., and Johnson, S. A. (1988) Liposome-encapsulated hemoglobin: oxygen binding properties and respiratory function. *Biomater. Artif. Cells Artif. Organs* 16, 289-299.
- (42) Rudolph, A. S., Klipper, R. W., Goins, B., and Phillips, W. T. (1991) In vivo biodistribution of a radiolabeled blood substitute: ^{99m}Tc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. *Proc. Natl. Acad. Sci. U.S.A.* 88, 10976-10980.
- (43) Phillips, W. T., Klipper, R. W., Awasthi, V. D., Rudolph, A. S., Cliff, R., Kwasiborski, V., and Goins, B. A. (1999) Polyethylene glycol-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. *J. Pharmacol. Exp. Ther.* 288, 665-670.
- (44) Usuba, A., Osuka, F., Kimura, T., Sato, R., Ogata, Y., Gotoh, H., Kimura, T., and Fukui, H. (1998) Effect of liposome-encapsulated hemoglobin, neo red cells, on hemorrhagic shock. *Surg. Today* 28, 1027-1035.
- (45) Yoshioka, H. (1991) Surface modification of haemoglobin-containing liposomes with polyethylene glycol prevents liposome aggregation in blood plasma. *Biomaterials* 12, 861-864.
- (46) Sakai, H., Hamada, K., Takeoka, S., Nishide, H., and Tsuchida, E. (1996) Physical properties of hemoglobin vesicles as red cell substitutes. *Biotechnol. Prog.* 12, 119-125.
- (47) Takeoka, S., Ohgushi, T., Terase, K., Ohmori, T., and Tsuchida, E. (1996) Layer-controlled hemoglobin vesicles by interaction of hemoglobin with a phospholipid assembly. *Langmuir* 12, 1755-1759.
- (48) Sou, K., Naito, Y., Endo, T., Takeoka, S., and Tsuchida, E. (2003) Effective encapsulation of proteins into size-controlled phospholipid vesicles using freeze-thawing and extrusion. *Biotechnol. Prog.* 19, 1547-1552.
- (49) Sakai, H., Takeoka, S., Yokohama, H., Seino, Y., Nishide, H., and Tsuchida, E. (1993) Purification of concentrated Hb using organic solvent and heat treatment. *Protein Expression Purif.* 4, 563-569.
- (50) Abe, H., Ikebuchi, K., Hirayama, J., Fujihara, M., Takeoka, S., Sakai, H., Tsuchida, E., and Ikeda, H. (2001) Virus inactivation in hemoglobin solution by heat treatment. *Artif. Cells Blood Substit. Immobil. Biotechnol.* 29, 381-388.
- (51) Chung, J., Hamada, K., Sakai, H., Takeoka, S., and Tsuchida, E. (1995) Ligand-exchange reaction of carbonylhemoglobin to oxyhemoglobin in a hemoglobin liquid membrane. *Nippon Kagaku Kaishi* 2, 123-127 (in Japanese).
- (52) Takeoka, S., Sakai, H., Kose, T., Mano, Y., Seino, Y., Nishide, H., and Tsuchida, E. (1997) Methemoglobin formation in hemoglobin vesicles and reduction by encapsulated thiols. *Bioconjugate Chem.* 8, 539-544.
- (53) Teramura, Y., Kanazawa, H., Sakai, H., Takeoka, S., and Tsuchida, E. (2003) Prolonged oxygen-carrying ability of hemoglobin vesicles by coencapsulation of catalase *in vivo*. *Bioconjugate Chem.* 14, 1171-1176.
- (54) Sakai, H., Masada, Y., Onuma, H., Takeoka, S., and Tsuchida, E. (2004) Reduction of methemoglobin via electron transfer from photoreduced flavin: restoration of O₂-binding of concentrated hemoglobin solution coencapsulated in phospholipid vesicles. *Bioconjugate Chem.* 15, 1037-1045.

- (55) Atoji, T., Aihara, M., Sakai, H., Tsuchida, E., and Takeoka, S. (2006) Hemoglobin vesicles containing methemoglobin and L-tyrosine to suppress methemoglobin formation *in vitro* and *in vivo*. *Bioconjugate Chem.* 17, 1241–1245.
- (56) Sakai, H., Takeoka, S., Seino, Y., and Tsuchida, E. (1994) Suppression of methemoglobin formation by glutathione in a concentrated hemoglobin solution and in a Hb-vesicle. *Bull. Chem. Soc. Jpn.* 67, 1120–1125.
- (57) Rameez, S., Alosta, H., and Palmer, A. F. (2008) Biocompatible and biodegradable polymersome encapsulated hemoglobin: a potential oxygen carrier. *Bioconjugate Chem.* 19, 1025–1032.
- (58) Zhao, J., Liu, C. S., Yuan, Y., Tao, X. Y., Shan, X. Q., Sheng, Y., and Wu, F. (2007) Preparation of hemoglobin-loaded nano-sized particles with porous structure as oxygen carriers. *Biomaterials* 28, 1414–1422.
- (59) Rudolph, A. S. (1988) The freeze-dried preservation of liposome encapsulated hemoglobin: a potential blood substitute. *Cryobiology* 25, 277–284.
- (60) Rabinovici, R., Rudolph, A. S., Vernick, J., and Feuerstein, G. (1994) Lyophilized liposome encapsulated hemoglobin: evaluation of hemodynamic, biochemical, and hematologic responses. *Crit. Care Med.* 22, 480–485.
- (61) Ringsdorf, H., Schlarb, B., and Venzmer, J. (1988) Molecular architecture and function of polymeric oriented systems - models for the study of organization, surface recognition, and dynamics of biomembranes. *Angew. Chem., Int. Ed.* 27, 113–158.
- (62) Kato, A., Arakawa, M., and Kondo, T. (1984) Preparation and stability of liposome-type artificial red blood cells stabilized with carboxymethylchitin. *J. Microencapsul.* 1, 105–112.
- (63) Mobed, M., Nishiya, T., and Chang, T. M. (1992) Preparation of carboxymethylchitin-incorporated submicron bilayer-lipid membrane artificial cells (liposomes) encapsulating hemoglobin. *Biomater. Artif. Cells Immobil. Biotechnol.* 20, 365–368.
- (64) Li, S., Nickels, J., and Palmer, A. F. (2005) Liposome-encapsulated actin-hemoglobin (LEAChb) artificial blood substitutes. *Biomaterials* 26, 3759–3769.
- (65) Tsuchida, E., Hasegawa, E., Kimura, N., Hatashita, M., and Makino, C. (1992) Polymerization of unsaturated phospholipids as large unilamellar liposomes at low temperature. *Macromolecules* 25, 2007–212.
- (66) Sakai, H., Takeoka, S., Yokohama, H., Nishide, H., and Tsuchida, E. (1992) Encapsulation of Hb into unsaturated lipid vesicles and gamma-ray polymerization. *Polym. Adv. Technol.* 3, 389–394.
- (67) Akama, K., Awai, K., Yano, Y., Tokuyama, S., and Nakano, Y. (2000) *In vitro* and *in vivo* stability of polymerized mixed liposomes composed of 2,4-octadecadienyl groups of phospholipids. *Polym. Adv. Technol.* 11, 280–287.
- (68) Sakai, H., Takeoka, S., Park, S. I., Kose, T., Nishide, H., Izumi, Y., Yoshizu, A., Kobayashi, K., and Tsuchida, E. (1997) Surface-modification of hemoglobin vesicles with poly(ethylene glycol) and effects on aggregation, viscosity, and blood flow during 90%-exchange transfusion in anesthetized rats. *Bioconjugate Chem.* 8, 23–30.
- (69) Sakai, H., Tsai, A. G., Kerger, H., Park, S. I., Takeoka, S., Nishide, H., Tsuchida, E., and Intaglietta, M. (1998) Subcutaneous microvascular responses to hemodilution with red cell substitutes consisting of polyethylene glycol-modified vesicles encapsulating hemoglobin. *J. Biomed. Mater. Res.* 40, 66–78.
- (70) Sakai, H., Okamoto, M., Ikeda, E., Horinouchi, H., Kobayashi, K., and Tsuchida, E. (2008) Histopathological changes of rat brain after direct injection of hemoglobin vesicles (oxygen carriers) and neurological impact in an intracerebral hemorrhage model. *J. Biomed. Mater. Res., Part A* (in press).
- (71) Sakai, H., Tomiyama, K., Sou, K., Takeoka, S., and Tsuchida, E. (2000) Poly(ethylene glycol)-conjugation and deoxygenation enable long-term preservation of hemoglobin vesicles as oxygen carriers in a liquid state. *Bioconjugate Chem.* 11, 425–432.
- (72) Sou, K., Endo, T., Takeoka, S., and Tsuchida, E. (2000) Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles. *Bioconjugate Chem.* 11, 372–379.
- (73) Sato, T., Sakai, H., Sou, K., Buchner, R., and Tsuchida, E. (2007) Poly(ethylene glycol)-conjugated phospholipids in aqueous micellar solutions: hydration, static structure, and interparticle interactions. *J. Phys. Chem. B* 111, 1393–1401.
- (74) Szebeni, J. (2005) Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. *Toxicology* 216, 106–121.
- (75) Van de Velde, M., Wouters, P. F., Rolf, N., Van Aken, H., and Vandermersch, E. (1998) Comparative hemodynamic effects of three different parenterally administered lipid emulsions in conscious dogs. *Crit. Care Med.* 26, 132–137.
- (76) Vercellotti, G. M., Hammerschmidt, D. E., Craddock, P. R., and Jacob, H. S. (1982) Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis. *Blood* 59, 1299–1304.
- (77) Phillips, W. T., Klipper, R., Fresne, D., Rudolph, A. S., Javors, M., and Goins, B. (1997) Platelet reactivity with liposome-encapsulated hemoglobin in the rat. *Exp. Hematol.* 25, 1347–1356.
- (78) Szebeni, J., Fontana, J. L., Wassef, N. M., Mongan, P. D., Morse, D. S., Dobbins, D. E., Stahl, G. L., Bunker, R., and Alving, C. R. (1999) Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. *Circulation* 99, 2302–2309.
- (79) Izumi, Y., Sakai, H., Kose, T., Hamada, K., Takeoka, S., Yoshizu, A., Horinouchi, H., Kato, R., Nishide, H., Tsuchida, E., and Kobayashi, K. (1999) Evaluation of the capabilities of a hemoglobin vesicle as an artificial oxygen carrier in a rat exchange transfusion model. *ASAIO J.* 43, 289–297.
- (80) Loughrey, H. C., Bally, M. B., Reinisch, L. W., and Cullis, P. R. (1990) The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. *Thromb. Haemost.* 64, 172–176.
- (81) Chonn, A., Cullis, P. R., and Devine, D. V. (1991) The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. *J. Immunol.* 146, 4234–4241.
- (82) Sou, K., and Tsuchida, E. (2008) Electrostatic interactions and complement activation on the surface of phospholipid vesicle containing acidic lipids: effect of the structure of acidic groups. *Biochim. Biophys. Acta - Biomembr.* 1778, 1035–1041.
- (83) Abe, H., Azuma, H., Yamaguchi, M., Fujihara, M., Ikeda, H., Sakai, H., Takeoka, S., and Tsuchida, E. (2007) Effects of hemoglobin vesicles, a liposomal artificial oxygen carrier, on hematological responses, complement and anaphylactic reactions in rats. *Artif. Cells Blood Substit. Biotechnol.* 35, 157–172.
- (84) Abe, H., Fujihara, M., Azuma, H., Ikeda, H., Ikebuchi, K., Takeoka, S., Tsuchida, E., and Harashima, H. (2006) Interaction of hemoglobin vesicles, a cellular-type artificial oxygen carrier, with human plasma: effects on coagulation, kallikrein-kinin, and complement systems. *Artif. Cells Blood Substit. Immobil. Biotechnol.* 34, 1–10.
- (85) Wakamoto, S., Fujihara, M., Abe, H., Yamaguchi, M., Azuma, H., Ikeda, H., Takeoka, S., and Tsuchida, E. (2005) Effects of hemoglobin vesicles on resting and agonist-stimulated human platelets *in vitro*. *Artif. Cells Blood Substit. Immobil. Biotechnol.* 33, 101–111.
- (86) Wakamoto, S., Fujihara, M., Abe, H., Sakai, H., Takeoka, S., Tsuchida, E., Ikeda, H., and Ikebuchi, K. (2001) Effects of poly(ethyleneglycol)-modified hemoglobin vesicles on agonist-induced platelet aggregation and RANTES release *in vitro*. *Artif. Cells Blood Substit. Immobil. Biotechnol.* 29, 191–201.

- (87) Takeoka, S., Mori, K., Ohkawa, H., Sou, K., and Tsuchida, E. (2000) Synthesis and assembly of poly(ethylene glycol)-lipids with mono-, di-, and tetraacyl chains and a poly(ethylene glycol) chain of various molecular weights. *J. Am. Chem. Soc.* **122**, 7927-7935.
- (88) Okamura, Y., Maekawa, I., Teramura, Y., Maruyama, H., Handa, M., Ikeda, Y., and Takeoka, S. (2005) Hemostatic effects of phospholipid vesicles carrying fibrinogen gamma chain dodecapeptide *in vitro* and *in vivo*. *Bioconjugate Chem.* **16**, 1589-1596.
- (89) Ohkawa, H., Teramura, Y., Takeoka, S., and Tsuchida, E. (2000) Synthesis of multiacyl poly(ethylene glycol) for the conjugation of cytochrome c to phospholipid vesicle. *Bioconjugate Chem.* **11**, 815-821.
- (90) Sou, K., Goins, B., Takeoka, S., Tsuchida, E., and Phillips, W. T. (2007) Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages *in vivo*. *Biomaterials* **28**, 2655-2666.
- (91) Teramura, Y., and Iwata, H. (2008) Islets surface modification prevents blood-mediated inflammatory responses. *Bioconjugate Chem.* **19**, 1389-1395.
- (92) Obata, Y., Suzuki, D., and Takeoka, S. (2008) Evaluation of cationic assemblies constructed with amino acid based lipids for plasmid DNA delivery. *Bioconjugate Chem.* **19**, 1055-1063.
- (93) Sou, K., Inenaga, S., Takeoka, S., and Tsuchida, E. (2008) Loading of curcumin into macrophages using lipid-based nanoparticles. *Int. J. Pharm.* **352**, 287-293.
- (94) Sou, K., Klipper, R., Goins, B., Tsuchida, E., and Phillips, W. T. (2005) Circulation kinetics and organ distribution of Hb vesicles developed as a red blood cell substitute. *J. Pharmacol. Exp. Ther.* **312**, 702-709.
- (95) Bradley, A. J., Devine, D. V., Ansell, S. M., Janzen, J., and Brooks, D. E. (1998) Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. *Arch. Biochem. Biophys.* **357**, 185-194.
- (96) Hu, Q., and Liu, D. (1996) Co-existence of serum-dependent and serum-independent mechanisms for liposome clearance and involvement of non-Kupffer cells in liposome uptake by mouse liver. *Biochim. Biophys. Acta* **1284**, 153-161.
- (97) Shibuya-Fujiwara, N., Hirayama, F., Ogata, Y., Ikeda, H., and Ikebuchi, K. (2001) Phagocytosis *in vitro* of polyethylene glycol-modified liposome-encapsulated hemoglobin by human peripheral blood monocytes plus macrophages through scavenger receptors. *Life Sci.* **70**, 291-300.
- (98) Sakai, H., Horinouchi, H., Tomiyama, K., Ikeda, E., Takeoka, S., Kobayashi, K., and Tsuchida, E. (2001) Hemoglobin-vesicles as oxygen carriers: influence on phagocytic activity and histopathological changes in reticuloendothelial system. *Am. J. Pathol.* **159**, 1079-1088.
- (99) Sakai, H., Horinouchi, H., Masada, Y., Takeoka, S., Kobayashi, K., and Tsuchida, E. (2004) Metabolism of hemoglobin-vesicles (artificial oxygen carriers) and their influence on organ functions in a rat model. *Biomaterials* **25**, 4317-4325.
- (100) Sakai, H., Masada, Y., Horinouchi, H., Ikeda, E., Sou, K., Takeoka, S., Suematsu, M., Takaori, M., Kobayashi, K., and Tsuchida, E. (2004) Physiologic capacity of reticuloendothelial system for degradation of hemoglobin-vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days. *J. Pharmacol. Exp. Ther.* **311**, 874-884.
- (101) Sakai, H., Horinouchi, H., Yamamoto, M., Ikeda, E., Takeoka, S., Takaori, M., Tsuchida, E., and Kobayashi, K. (2006) Acute 40% exchange-transfusion with hemoglobin-vesicles (HbV) suspended in recombinant human serum albumin solution: degradation of HbV and erythropoiesis in a rat spleen for 2 weeks. *Transfusion* **46**, 339-347.
- (102) Sakai, H., Seishi, Y., Obata, Y., Takeoka, S., Horinouchi, H., Tsuchida, E., and Kobayashi, K. (2009) Fluid resuscitation with artificial oxygen carriers in hemorrhaged rats: Profiles of hemoglobin-vesicle degradation and hematopoiesis for 14 days. *Shock* **31**, 192-200.
- (103) Yamaoka, T., Tabata, Y., and Ikada, Y. (1994) Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. *J. Pharm. Sci.* **83**, 601-606.
- (104) Ohki, N., Kimura, T., and Ogata, Y. (1998) The reduction of methemoglobin in Neo Red Cell. *Artif. Cells Blood Substit. Immobil. Biotechnol.* **26**, 477-485.
- (105) Sakai, H., Tsai, A. G., Rohlf, R. J., Hara, H., Takeoka, S., Tsuchida, E., and Intaglietta, M. (1999) Microvascular responses to hemodilution with Hb vesicles as red cell substitutes: Influences of O₂ affinity. *Am. J. Physiol. Heart Circ. Physiol.* **276**, H553-H562.
- (106) Wang, L., Morizawa, K., Tokuyama, S., Satoh, T., and Tsuchida, E. (1992) Modulation of oxygen-carrying capacity of artificial red cells (ARC). *Polym. Adv. Technol.* **4**, 8-11.
- (107) Cabrales, P., Sakai, H., Tsai, A. G., Takeoka, S., Tsuchida, E., and Intaglietta, M. (2005) Oxygen transport by low and normal oxygen affinity hemoglobin vesicles in extreme hemodilution. *Am. J. Physiol. Heart Circ. Physiol.* **288**, H1885-H1892.
- (108) Izumi, Y., Sakai, H., Hamada, K., Takeoka, S., Yamahata, T., Kato, R., Nishide, H., Tsuchida, E., and Kobayashi, K. (1996) Physiologic responses to exchange transfusion with hemoglobin vesicles as an artificial oxygen carrier in anesthetized rats: changes in mean arterial pressure and renal cortical oxygen tension. *Crit. Care Med.* **24**, 1869-1873.
- (109) Sakai, H., Takeoka, S., Wettstein, R., Tsai, A. G., Intaglietta, M., and Tsuchida, E. (2002) Systemic and Microvascular responses to the hemorrhagic shock and resuscitation with Hb vesicles. *Am. J. Physiol. Heart Circ. Physiol.* **283**, H1191-H1199.
- (110) Sakai, H., Masada, Y., Horinouchi, H., Yamamoto, M., Ikeda, E., Takeoka, S., Kobayashi, K., and Tsuchida, E. (2004) Hemoglobin vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. *Crit. Care Med.* **32**, 539-545.
- (111) Yoshizu, A., Izumi, Y., Park, S. I., Sakai, H., Takeoka, S., Horinouchi, H., Ikeda, E., Tsuchida, E., and Kobayashi, K. (2004) Hemorrhagic shock resuscitation with an artificial oxygen carrier hemoglobin vesicle (HbV) maintains intestinal perfusion and suppresses the increase in plasma necrosis factor alpha (TNF α). *ASAIO J.* **50**, 458-463.
- (112) Terajima, K., Tsueshita, T., Sakamoto, A., and Ogawa, R. (2006) Fluid resuscitation with hemoglobin vesicles in a rabbit model of acute hemorrhagic shock. *Shock* **25**, 184-189.
- (113) Yamazaki, M., Aeba, R., Yozu, R., and Kobayashi, K. (2006) Use of hemoglobin vesicles during cardiopulmonary bypass priming prevents neurocognitive decline in rats. *Circulation* **114** (1 Suppl), I220-I225.
- (114) Tsai, A. G., Vandegriff, K. D., Intaglietta, M., and Winslow, R. M. (2003) Targeted O₂ delivery by low-P₅₀ hemoglobin: a new basis for O₂ therapeutics. *Am. J. Physiol. Heart Circ. Physiol.* **285**, H1411-H1419.
- (115) Plock, J. A., Tromp, A. E., Contaldo, C., Spanholtz, T., Sinovic, D., Sakai, H., Tsuchida, E., Leunig, M., Banic, A., and Erni, D. (2007) Hemoglobin vesicles reduce hypoxia-related inflammation in critically ischemic hamster flap tissue. *Crit. Care Med.* **35**, 899-905.
- (116) Nolte, D., Pickelmann, S., Lang, M., Keipert, P., and Messmer, K. (2000) Compatibility of different colloid plasma expanders with perflubron emulsion: an intravital microscopic study in the hamster. *Anesthesiology* **93**, 1261-1270.
- (117) Jouan-Hureaux, V., Audonnet-Blaise, S., Lacatusu, D., Krafft, M. P., Dewachter, P., Cauchois, G., Stoltz, J. F., Longrois, D., and Menu, P. (2006) Effects of a new perfluorocarbon emulsion on human plasma and whole-blood viscosity in the presence of albumin, hydroxyethyl starch, or modified fluid gelatin: an *in vitro* rheologic approach. *Transfusion* **46**, 1892-1898.
- (118) Vandegriff, K. D., McCarthy, M., Rohlf, R. J., and Winslow, R. M. (1997) Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface-conjugated. *Biophys. Chem.* **69**, 23-30.

- (119) Kobayashi, K. (2006) Summary of recombinant human serum albumin development. *Biologicals* 34, 55–59.
- (120) Meyuhas, D., Nir, S., and Lichtenberg, D. (1996) Aggregation of phospholipid vesicles by water-soluble polymers. *Biophys. J.* 71, 2602–2612.
- (121) Neu, B., and Meiselman, H. J. (2002) Depletion-mediated red blood cell aggregation in polymer solutions. *Biophys. J.* 83, 2482–2490.
- (122) Sakai, H., Sato, A., Takeoka, S., and Tsuchida, E. (2007) Rheological property of hemoglobin vesicles (artificial oxygen carriers) suspended in a series of plasma substitute aqueous solutions. *Langmuir* 23, 8121–8128.
- (123) Tsai, A. G., Friesenecker, B., McCarthy, M., Sakai, H., and Intaglietta, M. (1998) Plasma viscosity regulates capillary perfusion during extreme hemodilution in hamster skinfold model. *Am. J. Physiol. Heart Circ. Physiol.* 275, H2170–H2180.
- (124) Intaglietta, M., Cabrales, P., and Tsai, A. G. (2006) Microvascular perspective of oxygen-carrying and non-carrying blood substitutes. *Annu. Rev. Biomed. Eng.* 8, 289–321.
- (125) Rebel, A., Ulatowski, J. A., Kwansa, H., Bucci, E., and Koehler, R. C. (2003) Cerebrovascular response to decreased hemotocrit: effect of cell-free hemoglobin, plasma viscosity, and CO₂. *Am. J. Physiol. Heart Circ. Physiol.* 285, H1600–H1608.
- (126) Dimino, M. L., and Palmer, A. F. (2007) High O₂ affinity hemoglobin-based oxygen carriers synthesized via polymerization of hemoglobin with ring-opened 2-chloroethyl-β-D-fructopyranoside and 1-o-octyl-β-D-glucopyranoside. *Biotechnol. Bioeng.* 97, 462–472.
- (127) Plock, J. A., Contaldo, C., Sakai, H., Tsuchida, E., Leunig, M., Banic, A., Menger, M. D., and Erni, D. (2005) Is the Hb in Hb vesicles infused for isovolemic hemodilution necessary to improve oxygenation in critically ischemic hamster skin? *Am. J. Physiol. Heart Circ. Physiol.* 289, H2624–H2631.
- (128) Contaldo, C., Plock, J., Sakai, H., Takeoka, S., Tsuchida, E., Leunig, M., Banic, A., and Erni, D. (2005) New generation of hemoglobin-based oxygen carriers evaluated for oxygenation of critically ischemic hamster flap tissue. *Crit. Care Med.* 33, 806–812.
- (129) Verdu, E. F., Bercik, P., Huang, X. X., Lu, J., Al-Mutawaly, N., Sakai, H., Tompkins, T. A., Croitoru, K., Tsuchida, E., Perdue, M., and Collins, S. M. (2008) The role of luminal factors in the recovery of gastric function and behavioral changes after chronic *Helicobacter pylori* infection. *Am. J. Physiol. Gastrointest. Liver Physiol.* 295, G664–G670.
- (130) Komatsu, H., Furuya, T., Sato, N., Ohta, K., Matsuura, A., Ohmura, T., Takagi, S., Matsuura, M., Yamashita, M., Ito, M., Itoh, J., Horinouchi, H., and Kobayashi, K. (2007) Effect of hemoglobin vesicle, a cellular-type artificial oxygen carrier, on middle cerebral artery occlusion- and arachidonic acid-induced stroke models in rats. *Neurosci. Lett.* 421, 121–125.
- (131) Yamamoto, M., Izumi, Y., Horinouchi, H., Teramura, Y., Sakai, H., Kohno, M., Watanabe, M., Kawamura, M., Adachi, T., Ikeda, E., Takeoka, S., Tsuchida, E., Kobayashi, K. (2009) Systemic administration of hemoglobin vesicle elevates tumor tissue oxygen tension and modifies tumor response to irradiation. *J. Surg. Res.* doi:10.1016/j.jss.2007.12.770.
- (132) Sakai, H., Horinouchi, H., Tsuchida, E., Kobayashi, K. (2008) Hemoglobin-vesicles and red blood cells as carriers of carbon monoxide prior to oxygen for resuscitation after hemorrhagic shock in a rat model. *Shock*. doi:10.1097/SHK.0b013e318189017a.
- (133) Peters, T. (1996) *All about Albumin: Biochemistry, Genetics and Medical Applications*, Academic Press, San Diego.
- (134) He, X. M., and Carter, D. C. (1992) Atomic structure and chemistry of human serum albumin. *Nature* 358, 209–215.
- (135) Carter, D. C., and Ho, J. X. (1994) Structure of serum albumin. *Adv. Protein Chem.* 45, 153–203.
- (136) Curry, S., Madelkow, H., Brick, P., and Franks, N. P. (1998) Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. *Nat. Struct. Biol.* 5, 827–835.
- (137) Bhattacharya, A. A., Grune, T., and Curry, S. (2000) Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. *J. Mol. Biol.* 303, 721–732.
- (138) Ghuman, J., Zunszain, P. A., Petitpas, I., Bhattacharya, A. A., Ottagiri, M., and Curry, S. (2007) Structural basis of the drug-binding specificity of humans serum albumin. *J. Mol. Biol.* 353, 38–52.
- (139) Tsuchida, E., Komatsu, T., Matsukawa, Y., Hamamatsu, K., and Wu, J. (1999) Human serum albumin incorporating tetrakis(o-pivalamido)phenyl porphinatoiron(II) derivative as a totally synthetic O₂-carrying hemoprotein. *Bioconjugate Chem.* 10, 797–802.
- (140) Komatsu, T., Hamamatsu, K., Wu, J., and Tsuchida, E. (1999) Physicochemical properties and O₂-coordination structure of human serum albumin incorporating tetrakis(o-pivalamido)phenylporphyrinatoiron(II) derivatives. *Bioconjugate Chem.* 10, 82–86.
- (141) Tsuchida, E., Komatsu, T., Yanagimoto, T., and Sakai, H. (2003) Preservation stability and *in vivo* administration of albumin-heme hybrid solution as an entirely synthetic O₂-carrier. *Polym. Adv. Technol.* 13, 848–850.
- (142) Huang, Y., Komatsu, T., Nakagawa, A., Tsuchida, E., and Kobayashi, S. (2003) Compatibility *in vitro* of albumin-heme (O₂ carrier) with blood cell components. *J. Biomed. Mater. Res.* 66A, 292–297.
- (143) Komatsu, T., Huang, Y., Wakamoto, S., Abe, H., Fujihara, M., Azuma, H., Ikeda, H., Yamamoto, H., Horinouchi, H., and Kobayashi, K. (2007) Influence of O₂-carrying plasma hemoprotein "albumin-heme" on complement system and platelet activation *in vitro* and physiological responses to exchange transfusion. *J. Biomed. Mater. Res.* 81A, 821–826.
- (144) Tsuchida, E., Nakagawa, A., and Komatsu, T. (2003) Coordination structure of active site in synthetic hemoprotein (albumin-heme) with dioxygen and carbon monoxide. *Macromol. Symp.* 195, 275–280.
- (145) Komatsu, T., Matsukawa, Y., and Tsuchida, E. (2000) Nitrosyl iron(II) complex of meso-tetrakis(α,α,α,α-o-pivalamidophenyl)porphyrin with a covalently linked 2-methylimidazolylalkyl group. *Chem. Lett.* 1060–1061.
- (146) Komatsu, T., Matsukawa, Y., and Tsuchida, E. (2001) Reaction of nitric oxide with synthetic hemoprotein, human serum albumin incorporating tetraphenylporphinatoiron(II) derivatives. *Bioconjugate Chem.* 12, 71–75.
- (147) Collman, J. P., Brauman, J. I., Iverson, B. L., Sessler, J. L., Morris, R. M., and Gibson, Q. H. (1983) O₂ and CO binding to iron(II) porphyrins: A comparison of the "picket fence" and "pocket" porphyrins. *J. Am. Chem. Soc.* 105, 3052–3064.
- (148) Traylor, T. G., Tsuchiya, S., Campbell, D., Mitchell, M., Stynes, D., and Koga, N. (1985) Anthracene-heme cyclophanes. Steric in CO, O₂ and RNC binding. *J. Am. Chem. Soc.* 107, 604–614.
- (149) Komatsu, T., Matsukawa, Y., and Tsuchida, E. (2000) Kinetics of CO and O₂ binding to human serum albumin-heme hybrid. *Bioconjugate Chem.* 11, 772–776.
- (150) Komatsu, T., Matsukawa, Y., and Tsuchida, E. (2002) Effect of heme structure on O₂-binding properties of human serum albumin-heme hybrids: intramolecular histidine coordination provides a stable O₂-adduct complex. *Bioconjugate Chem.* 13, 397–402.
- (151) Nakagawa, A., Komatsu, T., Iizuka, M., and Tsuchida, E. (2008) O₂ binding to human serum albumin incorporating iron porphyrin with a covalently linked methyl-L-histidine isomer. *Bioconjugate Chem.* 19, 581–584.
- (152) Nakagawa, A., Komatsu, T., and Tsuchida, E. (2007) meso-Tetrakis(α,α,α,α-o-amidophenyl) porphinatoiron(II) bearing a proximal histidyl group at the β-pyrrolic position via an acyl bond: synthesis and O₂ coordination in aqueous media. *Chem. Lett.* 36, 640–641.

- (153) Komatsu, T., Okada, T., Moritake, M., and Tsuchida, E. (2001) O₂-binding properties of double-sided porphyrinatoiron(II)s with polar substituents and their human serum albumin hybrids. *Bull. Chem. Soc. Jpn.* 74, 1695–1702.
- (154) Nakagawa, A., Komatsu, T., Iizuka, M., and Tsuchida, E. (2006) Human serum albumin hybrid incorporating tailed porphyrinatoiron(II) in the $\alpha_1\alpha_2\beta\beta$ -conformer as an O₂-binding site. *Bioconjugate Chem.* 17, 146–151.
- (155) Nakagawa, A., Komatsu, T., Ohmichi, N., and Tsuchida, E. (2003) Synthetic dioxygen-carrying hemoprotein. human serum albumin including iron(II) complex of protoporphyrin IX with an axially coordinated histidylglycyl-propionate. *Chem. Lett.* 32, 504–505.
- (156) Nakagawa, A., Komatsu, T., Ohmichi, N., and Tsuchida, E. (2004) Synthesis of protoheme IX derivatives with a covalently linked proximal base and their human serum albumin hybrids as artificial hemoprotein. *Org. Biomol. Chem.* 2, 3108–3112.
- (157) Wang, R.-M., Komatsu, T., Nakagawa, A., and Tsuchida, E. (2005) Human serum albumin bearing covalently attached iron(II) porphyrins as O₂-coordination sites. *Bioconjugate Chem.* 16, 23–26.
- (158) Harris, J. M. (1992) *Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications* (Harris, J. M., Ed.) Plenum Press, New York.
- (159) Veronese, F. M., and Harris, J. M. (2002) Introduction and overview of peptide and protein PEGylation. *Adv. Drug Delivery Rev.* 54, 453–456.
- (160) Roberts, M. J., Bentley, M. D., and Harris, J. M. (2002) Chemistry for peptide and protein PEGylation. *Adv. Drug Delivery Rev.* 54, 459–476.
- (161) Veronese, F. M. (2001) Peptide and protein PEGylation: a review of problems and solutions. *Biomaterials* 22, 405–417.
- (162) Nucci, M. L., Shorr, R., and Abuchowski, A. (1991) The therapeutic value of poly(ethylene glycol) modified proteins. *Adv. Drug Delivery Rev.* 6, 133–151.
- (163) Kawahara, N. Y., and Ohno, H. (1997) Induced thermostability of poly(ethylene oxide)-modified hemoglobin in glycols. *Bioconjugate Chem.* 8, 643–648.
- (164) Huang, Y., Komatsu, T., Wang, R.-M., Nakagawa, A., and Tsuchida, E. (2006) Poly(ethylene glycol)-conjugated human serum albumin including iron porphyrins: surface modification improves the O₂-transporting ability. *Bioconjugate Chem.* 17, 393–398.
- (165) Cabrales P., Tsai, A. G., Intaglietta, M. (2004) Microvascular pressure and functional capillary density in extreme hemodilution with low- and high-viscosity dextran and a low-viscosity Hb-based O₂ carrier. *Am. J. Physiol. Heart Circ. Physiol.* 287, H363–H373.
- (166) Martini, J., Cabrales, P., K. A., Acharya, S. A., Intaglietta, M., Tsai, A. G. (2008) Survival time in severe hemorrhagic shock after perioperative hemodilution is longer with PEG-conjugated human serum albumin than HES 130/0.4: a microvascular perspective. *Crit. Care* 12, R54.
- (167) Sugawara, Y., and Shikama, K. (1980) Autoxidation of native oxymyoglobin. *Eur. J. Biochem.* 110, 241–246.
- (168) Tsuchida, E., Komatsu, T., Hamamatsu, K., Matsukawa, Y., Tajima, A., Yoshizu, A., Izumi, Y., and Kobayashi, K. (2000) Exchange transfusion with albumin-heme as an artificial O₂-infusion into anesthetized rats: physiological responses, O₂-delivery, and reduction of the oxidized heme sites by red blood cells. *Bioconjugate Chem.* 11, 46–50.
- (169) Huang, Y., Komatsu, T., Yamamoto, H., Horinouchi, H., Kobayashi, K., and Tsuchida, E. (2006) PEGylated albumin-heme as an oxygen-carrying plasma expander: exchange transfusion into acute anemia rat model. *Biomaterials* 27, 4477–4483.
- (170) Tsuchida, E., Komatsu, T., Matsukawa, Y., Nakagawa, A., Sakai, H., Kobayashi, K., and Suematsu, M. (2003) Human serum albumin incorporating synthetic heme: red blood cell substitute without hypertension by nitric oxide scavenging. *J. Biomed. Mater. Res.* 64A, 257–261.
- (171) Nakagawa, A., Komatsu, T., Huang, H., Lu, G., and Tsuchida, E. (2007) O₂-binding albumin thin films: solid membranes of poly(ethylene glycol)-conjugated human serum albumin incorporating iron porphyrin. *Bioconjugate Chem.* 18, 1673–1677.
- (172) Goa, K. L., and Benfield, P. (1994) Hyaluronic-acid - a review of its pharmacology and use as a surgical and in ophthalmology, and its therapeutic potential in joint disease and wound-healing. *Drugs* 47, 536–566.
- (173) Adams, P. A., and Berman, M. C. (1980) Kinetics and mechanism of the interaction between human serum albumin and monomeric haem. *Biochem. J.* 191, 95–102.
- (174) Zunszain, P. A., Ghuman, J., Komatsu, T., Tsuchida, E., and Curry, S. (2003) Crystal structural analysis of human serum albumin complexed with heme and fatty acid. *BMC Struct. Biol.* 3, 6.
- (175) Wardell, M., Wang, Z., Ho, J. X., Robert, J., Ruker, F., Ruble, J., and Carter, D. C. (2002) The atomic structure of human methemalbumin at 1.9 Å. *Biochem. Biophys. Res. Commun.* 291, 813–819.
- (176) Komatsu, T., Ohmichi, N., Zunszain, P. A., Curry, S., and Tsuchida, E. (2004) Dioxygenation of human serum albumin having a prosthetic-heme group in a tailor-made heme pocket. *J. Am. Chem. Soc.* 126, 14304–14305.
- (177) Komatsu, T., Ohmichi, N., Nakagawa, A., Zunszain, P. A., Curry, S., and Tsuchida, E. (2005) O₂ and CO binding properties of artificial hemoproteins formed by complexing iron protoporphyrin IX with human serum albumin mutants. *J. Am. Chem. Soc.* 127, 15933–15942.
- (178) Vickery, L., Nozawa, T., and Sauer, K. (1976) Magnetic circular dichroism studies of myoglobin complexes. Correlation with-heme spin state and axial ligation. *J. Am. Chem. Soc.* 98, 343–350.
- (179) Antonini, E., and Brunori, M. *Hemoglobin and Myoglobin in Their Reactions with Ligands*, p 18, North-Holland Publishers, Amsterdam.
- (180) Rohlfs, R., Mathews, A. J., Carver, T. E., Olson, J. S., Springer, B. A., Egeberg, K. D., and Sligar, S. G. (1990) The effects of amino acid substitution at position E7 (residue 64) on the kinetics of ligand binding to sperm whale myoglobin. *J. Biol. Chem.* 265, 3168–3176.
- (181) Imai, K., Morimoto, H., Kotani, M., Watari, H., Hirata, W., and Kuroda, M. (1970) Studies of the function of abnormal hemoglobins I. An improved method for automatic measurement of the oxygen equilibrium curve of hemoglobin. *Biochim. Biophys. Acta* 200, 189–197.
- (182) Vandegriff, K. D., Young, M. A., Lohman, J., Bellelli, A., Samaja, M., Malavalli, A., and Winslow, R. M. (2008) CO-MP4, a polyethylene glycol-conjugated haemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats. *Br. J. Pharmacol.* 154, 1649–1661.
- (183) Creighton, T. E. (1992) *Proteins: Structures and Molecular Properties*, p 242, W. H. Freeman and Co., New York.
- (184) Chu, M. M. L., Castro, C. E., and Hathaway, G. M. (1978) Oxidation of low-spin iron(II) porphyrins by molecular oxygen. An outer sphere mechanism. *Biochemistry* 17, 481–486.
- (185) Tsuchida, E., Nishide, H., Sato, Y., and Kaneda, M. (1982) The preparation of protoheme mono-N-[5-(2-methyl-1-imidazolyl)pentyl]amide and its oxygenation. *Bull. Chem. Soc. Jpn.* 55, 1890–1895.
- (186) Uno, T., Sakamoto, R., and Tomisugi, Y. (2003) Inversion of axial coordination in myoglobin to create a "proximal" ligand binding pocket. *Biochemistry* 42, 10191–10199.
- (187) Springer, B. A., Sligar, S. G., Olson, J. S., and Philips, G. N. (1994) Mechanisms of a ligand recognition in myoglobin. *Chem. Rev.* 94, 699–714.
- (188) Komatsu, T., Nakagawa, A., Zunszain, P. A., Curry, S., and Tsuchida, E. (2007) Genetic engineering of the heme pocket in human serum albumin: modulation of O₂ binding of iron protoporphyrin IX by variation of distal amino acids. *J. Am. Chem. Soc.* 129, 11286–11295.

ヘモグロビン小胞体を含む血液検体の臨床検査 -デキストラン添加による干渉作用の回避-

Clinical Laboratory Test of Blood Specimens Containing Hemoglobin-vesicles - Interference Avoidance by Addition of Dextran-

宗慶太郎⁽¹⁾, 小峰梨沙⁽²⁾, 酒井宏水⁽¹⁾, 小林 絃一⁽³⁾, 土田 英俊⁽¹⁾, 村田 満⁽²⁾

Keitaro Sou⁽¹⁾, Risa Komine⁽²⁾, Hiromi Sakai⁽¹⁾, Koichi Kobayashi⁽³⁾, Eishun Tsuchida⁽¹⁾, Mitsuru Murata⁽²⁾

和文抄録

ヘモグロビン (Hb) 小胞体 (250 nm) は赤血球 (8 μm) に比べ1/30程度の大きさの人工酸素運搬体である。Hb小胞体を含む血液検体を遠心分離操作するとHb小胞体は血清に浮遊し、Hb小胞体による干渉作用が血液生化学検査を阻害することが解っているが、その他にも免疫学検査、凝固線溶検査、血糖検査などにおけるHb小胞体の干渉作用を検討する必要がある。本研究では、これらの検査におけるHb小胞体の干渉作用を明らかにすると共に、その回避法を明らかにすることを目的とした。遠心分離により血球と同時にHb小胞体を沈降分離させるため、各種分子量のデキストラン (Dex) を添加して血液中のHb小胞体を凝集させる条件を設定した。さらにヒト血液にHb小胞体を15vol%混合した試料についてこの分離条件を適用し、各検査項目について干渉の有無を検討した。Dexの分子量 (487 kDa) および濃度 (終濃度: 2.6g/dL) の設定により、通常の遠心分離 (3000-5000 rpm, 10 min) でHb小胞体を沈降分離できることを確認した。Hb小胞体は生化学および凝固線溶検査の多くの項目で干渉作用を示したものの、Dexを添加して遠心除去することにより大部分の項目で干渉を回避できた。ただし、Dex添加により生化学検査でリポ蛋白の低下、および凝固線溶検査でvon Willebrand factor (vWF) 活性の低下、トータル plasminogen activator inhibitor type-1 (PAI-1) の上昇を認め、これらについてはDex添加による干渉を受ける項目として注意を要する。血糖検査として検討したグルコースとグリコヘモグロビンはHb小胞体とDexの干渉なく測定できた。従って、Hb小胞体投与後の血液検体に本法を利用すれば、従来通り遠心分離で血清や血漿が得られ、生化学・免疫学検査、凝固線溶検査、血糖検査の多くの項目で干渉なく検査ができる。

Abstract

Hemoglobin-vesicle (HbV) is an artificial oxygen carrier of which size (250 nm) is 30 times smaller than red blood cells (8 μm). HbVs remain in serum after centrifugation because of its small size and as a result, HbV interferes with the clinical laboratory test. Here we examine the interference of HbV in other clinical laboratory tests such as immunological test, coagulation fibrinolysis examination, and blood sugar test. To precipitate the HbV by conventional centrifugal separation of blood, we determined an appropriate condition to aggregate HbV by an addition of Dextran (Dex). The obtained plasma or serum was evaluated by common clinical laboratory test. HbV could be precipitated by addition of Dex (Mw. 489 kDa, final concentration: 2.6 g/dL in blood) with conventional centrifugation (3000-5000 rpm, 10 min). Though the presence of HbV interfered with the measurement of many analytes, the interference could be removed by the addition of Dex. However, it should be cautioned that this method underestimates lipoprotein concentration and von Willebrand factor (vWF) activity, and overestimates total plasminogen activator inhibitor type-1 (PAI-1). Blood sugar tests for glucose and glycated hemoglobin (Hb_{A1c}) could be performed without interference effect of HbV and Dex. Taken together, the present method will be useful to separate serum

(1) 早稲田大学 理工学術院 理工学研究所 Research Institute for Science and Engineering, Waseda University

(2) 慶應義塾大学 医学部 臨床検査医学 〒160-8582 東京都新宿区信濃町35 Department of Laboratory Medicine, School of Medicine, Keio University, 35 Shinano-cho Shinjuku-ku Tokyo 160-8582, Japan

(3) 慶應義塾大学 医学部 呼吸器外科 Department of Thoracic Surgery, School of Medicine, Keio University

論文受付 2009年●月●日 論文受理 2009年1月30日

and plasma from the blood specimens containing HbV for accurate clinical laboratory tests.

Keywords

Hemoglobin-vesicles, oxygen carrier, blood specimen, clinical laboratory test, interference, dextran

1. はじめに

輸血代替物として人工酸素運搬体の使用が想定される救命救急や大手術では、各種の臨床検査やモニタリングにより患者の容態の管理が行われる。大量に投与される人工酸素運搬体の臨床応用を円滑に進めるには、人工酸素運搬体の投与により周辺の医療技術や機器にどのような影響を及ぼすか把握しておく必要がある。これまでに、血液検体検査のほか、Co-oximetry, pulse oximeter, あるいは magnetic resonance (MR) oximetry による酸素飽和度のモニタリングなどにおいて人工酸素運搬体の影響が調べられてきている¹⁻³⁾。Hb ベース、パーフルオロカーボン (PFC) ベースを含め、人工酸素運搬体は血球成分に比較して小粒径のため、遠心分離を経てなお血漿層に浮遊する。このため、人工酸素運搬体の特性吸収や濁度が血液生化学検査の多くの項目で測定値に影響を与える。血漿タンパク質と同程度の大きさの修飾 Hb は実験的にも血漿から分離するのが極めて困難であり、干渉作用の少ない機器の選定や修飾 Hb 濃度の関数として干渉分の補正係数を算出することで対処せざるを得ない^{4,5)}。ただし、干渉は濃度だけでなく、経時的に変化する MetHb 含量などの影響を受けるため⁶⁾、実際にはこれらの因子を複合的に考慮した補正が必要となる。特定の測定機種について独自の補正を含めた解析手法は臨床試験データの詳細解析には有効と思われるが、補正係数が測定機種に依存するため一般に普及する方法としては適していない。

一方、リン脂質二分子膜で Hb 溶液を被覆した Hb 小胞体 (250 nm) は、赤血球 (8 μm) に比較すれば 1/30 程度の大きさであるが、血漿タンパク質や修飾 Hb (数 nm) に比較すれば数十倍の大きさがある。この大きさになると、超遠心分離機を使用すれば比較的短時間で沈降させることができ、また、デキストランなど高分子凝集剤の添加により Hb 小胞体を凝集させれば、遠心分離操作で血清から Hb 小胞体を分離できる。このような分離法の工夫により血液生化学検査における干渉を回避できることがわかっている^{7,8)}。本研究では、デキストラン添加による Hb 小胞体の凝集現象を利用し、血液から段階的遠心分離操作により血漿や血清を分離する条件を検討した。更にこの条件で得られる血清や血漿について生化学・免疫検査、凝固検査、血糖検査を実施し、Hb 小胞体による干渉作用を回避できる項目、およびデキストラン添加による干渉作用のある項目を明らかにすることを目的とした。

2. 実験方法

2.1. デキストラン (Dex) 添加による Hb 小胞体の凝集

市販の分子量の異なる Dex 粉末 (分子量; 11, 19.6, 40.2, 72.2, 124, および 487 kDa, SIGMA) を生理食塩水に溶解させて高分

子凝集剤として使用した。Hb 小胞体分散液 (Hb; 0.05 g/dL, 3 mL) と Dex 溶液 (20 g/dL, 0.3 mL) を混合し (Dex 終濃度: 1.8 g/dL), 25℃ に静置して溶液濁度の変化 ($\lambda = 700$ nm) から凝集を検出し、その経時変化を観測した。この結果から Hb 小胞体の凝集生起に要する Dex 分子量および時間に関する知見を得た。

2.2. 血清分離条件の検討

Hb 小胞体が浮遊する血液から血清を分離する実験では、出血蘇生試験のため Hb 小胞体を投与したビーグル犬から採取した血液を使用した⁹⁾。循環血液量の 50% を脱血した後に、同量の Hb 小胞体分散液 ([Hb]=8.6 g/dL, 5% リコンビナントアルブミンに浮遊) を投与し、4 時間経過した時点での採血液を利用した。採血液 (5 mL) と Dex 溶液 (20 g/dL, 0.5 ~ 0.88 mL) を混合し、25℃ で 10 分間静置した。この混合液を遠心分離 (5000 rpm, 10 分) して上澄み液からの Hb 小胞体の除去を観測した。これらの結果から、Dex の分子量と濃度について Hb 小胞体を完全に除去できる条件を決定した。

2.3. ヒト血液検体検査

健康成人から採血した新鮮血 8.5 容に対し Hb 小胞体を 1.5 容の割合で混合し各種採血管 (ベノJECT II, テルモ) に分注した。さらに予め Dex (分子量 400 ~ 500 kDa, SIGMA) を 20 g/dL になるよう生理食塩水に溶解した溶液を終濃度 2.6 g/dL で添加混合した。10 分間室温放置後 3000 rpm, 10 分遠心分離し血清または血漿を得た。得られた血清の生化学検査 [総タンパク、アルブミン、総ビリルビン、アスパラギン酸アミノトランスフェラーゼ (AST), アラニンアミノトランスフェラーゼ (ALT), γ グルタミルトランスペプチダーゼ (γ -GTP), 乳酸脱水素酵素 (LDH), ロイシンアミノペプチダーゼ (LAP), クレアチンキナーゼ (CK), コリンエステラーゼ (ChE), 尿素窒素, 尿酸, 総コレステロール, エステル型コレステロール, 遊離型コレステロール, トロンボポエチン (A), トリグリセライド, リン脂質, 遊離脂肪酸, 高密度リポタンパク質-コレステロール (HDL-C) 定量, カリウム, カルシウム, 無機リン, クレアチニン, C 反応性蛋白 (CRP) 定量, フェリチン, ハプトグロビン], 免疫学検査 [免疫グロブリン G (IgG), 免疫グロブリン M (IgM), B 型肝炎ウイルス表面 (HBs) 抗原, B 型肝炎ウイルス表面 (HBs) 抗体, B 型肝炎ウイルス (HCV) 抗体], 血漿の凝固検査 [活性化部分トロンボプラスチン時間 (APTT), プロトロンビン時間 (PT), アンチトロンビン III (ATIII), トータルプラスミノーゲンアクチベーターインヒビター-1 (PAI-1), フィブリノゲン, フォン・ヴィレブランド因子 (vWF) 抗原, vWF 活性, D-ダイマー, フィブリン分